Trial Outcomes & Findings for A Study to Evaluate a Modified RNA Vaccine Against Influenza in Adults 18 Years of Age or Older (NCT NCT05540522)

Last Updated: 2025-05-08

Results Overview

LCI was defined as influenza infection confirmed through through reverse transcription- polymerase chain reaction (RT-PCR) or culture at the central laboratory, unless otherwise specified. Per-protocol ILI was defined as occurrence (new onset or worsening of preexisting condition) of at least 1 respiratory symptoms concurrently with at least 1 systemic symptoms. Data was obtained during the 2022-2023 northern hemisphere influenza season up to surveillance cut-off decided by Sponsor.

Recruitment status

COMPLETED

Study phase

PHASE3

Target enrollment

45789 participants

Primary outcome timeframe

Day 15 to surveillance cut-off (approximately 6 months)

Results posted on

2025-05-08

Participant Flow

Participants from northern hemisphere 2022-2023 and southern hemisphere 2023 were to be enrolled during respective influenza seasons and were stratified into 2 age groups: 18 to 64 years and more than or equal to (\>=) 65 years.

Participant milestones

Participant milestones
Measure	qIRV: 18-64 Years Participants aged 18-64 years were randomized to receive a single dose of quadrivalent influenza modified ribonucleic acid (modRNA) vaccine (qIRV) dose level 1 (low) intramuscularly (IM) on Day 1.	Licensed QIV: 18-64 Years Participants aged 18-64 years were randomized to receive a single dose of seasonal licensed quadrivalent influenza vaccine (QIV) IM per investigational product manual (IPM) on Day 1.	qIRV: >=65 Years Participants aged \>=65 years were randomized to receive a single dose of qIRV dose level 2 (high) IM on Day 1.	Licensed QIV: >=65 Years Participants aged \>=65 years were randomized to receive a single dose of seasonal licensed QIV IM per IPM on Day 1.
Overall Study STARTED	9247	9251	13635	13656
Overall Study Safety Set	9191	9197	13557	13611
Overall Study COMPLETED	8527	8598	13026	13043
Overall Study NOT COMPLETED	720	653	609	613

Reasons for withdrawal

Reasons for withdrawal
Measure	qIRV: 18-64 Years Participants aged 18-64 years were randomized to receive a single dose of quadrivalent influenza modified ribonucleic acid (modRNA) vaccine (qIRV) dose level 1 (low) intramuscularly (IM) on Day 1.	Licensed QIV: 18-64 Years Participants aged 18-64 years were randomized to receive a single dose of seasonal licensed quadrivalent influenza vaccine (QIV) IM per investigational product manual (IPM) on Day 1.	qIRV: >=65 Years Participants aged \>=65 years were randomized to receive a single dose of qIRV dose level 2 (high) IM on Day 1.	Licensed QIV: >=65 Years Participants aged \>=65 years were randomized to receive a single dose of seasonal licensed QIV IM per IPM on Day 1.
Overall Study Adverse Event	1	0	2	5
Overall Study Lost to Follow-up	487	427	146	166
Overall Study Physician Decision	11	19	8	13
Overall Study Pregnancy	1	0	0	0
Overall Study Protocol Violation	3	1	9	7
Overall Study Withdrawal by Subject	168	134	331	322
Overall Study Death	7	9	49	46
Overall Study Not vaccinated	34	53	57	50
Overall Study No longer meets eligibility criteria	0	0	3	2
Overall Study Other (Unspecified)	8	10	4	2

Baseline Characteristics

A Study to Evaluate a Modified RNA Vaccine Against Influenza in Adults 18 Years of Age or Older

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	qIRV: 18-64 Years n=9191 Participants Participants aged 18-64 years were randomized to receive a single dose of modRNA qIRV dose level 1 (low) IM on Day 1.	Licensed QIV: 18-64 Years n=9197 Participants Participants aged 18-64 years were randomized to receive a single dose of seasonal licensed QIV IM per IPM on Day 1.	qIRV: >=65 Years n=13557 Participants Participants aged \>=65 years were randomized to receive a single dose of qIRV dose level 2 (high) IM on Day 1.	Licensed QIV: >=65 Years n=13611 Participants Participants aged \>=65 years were randomized to receive a single dose of seasonal licensed QIV IM per IPM on Day 1.	Total n=45556 Participants Total of all reporting groups
Age, Continuous	42.9 Years STANDARD_DEVIATION 13.05 • n=5 Participants	43.1 Years STANDARD_DEVIATION 13.07 • n=7 Participants	70.9 Years STANDARD_DEVIATION 4.91 • n=5 Participants	70.8 Years STANDARD_DEVIATION 4.84 • n=4 Participants	59.6 Years STANDARD_DEVIATION 16.44 • n=21 Participants
Sex: Female, Male Female	5395 Participants n=5 Participants	5293 Participants n=7 Participants	7649 Participants n=5 Participants	7665 Participants n=4 Participants	26002 Participants n=21 Participants
Sex: Female, Male Male	3796 Participants n=5 Participants	3904 Participants n=7 Participants	5908 Participants n=5 Participants	5946 Participants n=4 Participants	19554 Participants n=21 Participants
Ethnicity (NIH/OMB) Hispanic or Latino	1961 Participants n=5 Participants	1955 Participants n=7 Participants	2041 Participants n=5 Participants	2094 Participants n=4 Participants	8051 Participants n=21 Participants
Ethnicity (NIH/OMB) Not Hispanic or Latino	7152 Participants n=5 Participants	7156 Participants n=7 Participants	11409 Participants n=5 Participants	11430 Participants n=4 Participants	37147 Participants n=21 Participants
Ethnicity (NIH/OMB) Unknown or Not Reported	78 Participants n=5 Participants	86 Participants n=7 Participants	107 Participants n=5 Participants	87 Participants n=4 Participants	358 Participants n=21 Participants
Race (NIH/OMB) American Indian or Alaska Native	73 Participants n=5 Participants	69 Participants n=7 Participants	37 Participants n=5 Participants	42 Participants n=4 Participants	221 Participants n=21 Participants
Race (NIH/OMB) Asian	372 Participants n=5 Participants	350 Participants n=7 Participants	1657 Participants n=5 Participants	1691 Participants n=4 Participants	4070 Participants n=21 Participants
Race (NIH/OMB) Native Hawaiian or Other Pacific Islander	24 Participants n=5 Participants	32 Participants n=7 Participants	64 Participants n=5 Participants	70 Participants n=4 Participants	190 Participants n=21 Participants
Race (NIH/OMB) Black or African American	1734 Participants n=5 Participants	1753 Participants n=7 Participants	2567 Participants n=5 Participants	2562 Participants n=4 Participants	8616 Participants n=21 Participants
Race (NIH/OMB) White	6780 Participants n=5 Participants	6759 Participants n=7 Participants	8974 Participants n=5 Participants	8992 Participants n=4 Participants	31505 Participants n=21 Participants
Race (NIH/OMB) More than one race	67 Participants n=5 Participants	88 Participants n=7 Participants	58 Participants n=5 Participants	60 Participants n=4 Participants	273 Participants n=21 Participants
Race (NIH/OMB) Unknown or Not Reported	141 Participants n=5 Participants	146 Participants n=7 Participants	200 Participants n=5 Participants	194 Participants n=4 Participants	681 Participants n=21 Participants

PRIMARY outcome

Timeframe: Day 15 to surveillance cut-off (approximately 6 months)

Population: Evaluable efficacy population included all participants who were eligible, received the study intervention to which they were randomized, and had no important protocol deviations, with surveillance starting at least 14 days after vaccination.

Outcome measures

Outcome measures
Measure	qIRV: 18-64 Years n=9118 Participants Participants aged 18-64 years were randomized to receive a single dose of modRNA qIRV dose level 1 (low) IM on Day 1.	Licensed QIV: 18-64 Years n=9120 Participants Participants aged 18-64 years were randomized to receive a single dose of seasonal licensed QIV IM per IPM on Day 1.
Percentage of Participants Reporting First Episode of LCI Cases With Associated Per-Protocol ILI Caused by Any Strain at Least 14 Days After Vaccination: 18-64 Years	0.63 Percentage of participants	0.95 Percentage of participants

PRIMARY outcome

Timeframe: Day 15 up to primary surveillance cut-off (approximately 1 year)

Population: Evaluable efficacy population analyzed.

LCI was defined as influenza infection confirmed through RT-PCR or culture at the central laboratory, unless otherwise specified. Per-protocol ILI was defined as occurrence (new onset or worsening of preexisting condition) of at least 1 respiratory symptoms concurrently with at least 1 systemic symptoms. Data was obtained during the 2022-2023 northern and southern hemisphere influenza season up to surveillance cut-off decided by Sponsor.

Outcome measures

Outcome measures
Measure	qIRV: 18-64 Years n=13392 Participants Participants aged 18-64 years were randomized to receive a single dose of modRNA qIRV dose level 1 (low) IM on Day 1.	Licensed QIV: 18-64 Years n=13456 Participants Participants aged 18-64 years were randomized to receive a single dose of seasonal licensed QIV IM per IPM on Day 1.
Percentage of Participants Reporting First Episode of Laboratory-Confirmed Influenza (LCI) Cases With Associated Per-Protocol Influenza-Like Illness (ILI) Caused by Any Strain at Least 14 Days After Vaccination: >= 65 Years	0.59 Percentage of participants	0.56 Percentage of participants

PRIMARY outcome

Timeframe: From Day 1 to Day 7 after study vaccination

Population: Reactogenicity e-diary safety included all participants who received the study intervention and had at least 1 day of e-diary data transferred for reactogenicity.

Local reactions included redness, swelling and pain at the injection site and were recorded by participants in an e-diary. All local reactions were graded based on Center for Biologics Evaluation and Research (CBER) toxicity guidelines as Grade 1 (Mild), Grade 2 (Moderate), Grade 3 (Severe) and Grade 4 (potentially life-threatening). In this outcome measure data is reported for any local reaction and any grade.

Outcome measures

Outcome measures
Measure	qIRV: 18-64 Years n=3060 Participants Participants aged 18-64 years were randomized to receive a single dose of modRNA qIRV dose level 1 (low) IM on Day 1.	Licensed QIV: 18-64 Years n=3067 Participants Participants aged 18-64 years were randomized to receive a single dose of seasonal licensed QIV IM per IPM on Day 1.
Percentage of Participants Reporting Any Local Reactions Within 7 Days After Study Vaccination: 18-64 Years	70.1 Percentage of participants Interval 68.5 to 71.7	43.1 Percentage of participants Interval 41.3 to 44.9

PRIMARY outcome

Timeframe: From Day 1 to Day 7 after study vaccination

Population: Reactogenicity e-diary safety set analyzed.

Outcome measures

Outcome measures
Measure	qIRV: 18-64 Years n=3563 Participants Participants aged 18-64 years were randomized to receive a single dose of modRNA qIRV dose level 1 (low) IM on Day 1.	Licensed QIV: 18-64 Years n=3563 Participants Participants aged 18-64 years were randomized to receive a single dose of seasonal licensed QIV IM per IPM on Day 1.
Percentage of Participants Reporting Any Local Reactions Within 7 Days After Study Vaccination: >=65 Years	68.7 Percentage of participants Interval 67.2 to 70.3	25.8 Percentage of participants Interval 24.4 to 27.3

PRIMARY outcome

Timeframe: From Day 1 to Day 7 after study vaccination

Population: Reactogenicity e-diary safety set analyzed.

Systemic events (vomiting, diarrhoea, headache, Fatigue/tiredness, chills, new or worsened muscle pain and joint pain) were recorded by participants in an e-diary. All systemic events were graded based on CBER toxicity guidelines as Grade 1 (Mild), Grade 2 (Moderate), Grade 3 (Severe) and Grade 4 (potentially life-threatening). In this outcome measure data is reported for any systemic reaction and any grade.

Outcome measures

Outcome measures
Measure	qIRV: 18-64 Years n=3060 Participants Participants aged 18-64 years were randomized to receive a single dose of modRNA qIRV dose level 1 (low) IM on Day 1.	Licensed QIV: 18-64 Years n=3067 Participants Participants aged 18-64 years were randomized to receive a single dose of seasonal licensed QIV IM per IPM on Day 1.
Percentage of Participants Reporting Any Systemic Events Within 7 Days After Study Vaccination: 18-64 Years	65.8 Percentage of participants Interval 64.0 to 67.4	48.7 Percentage of participants Interval 46.9 to 50.5

PRIMARY outcome

Timeframe: From Day 1 to Day 7 after study vaccination

Population: Reactogenicity e-diary safety set analyzed.

Outcome measures

Outcome measures
Measure	qIRV: 18-64 Years n=3563 Participants Participants aged 18-64 years were randomized to receive a single dose of modRNA qIRV dose level 1 (low) IM on Day 1.	Licensed QIV: 18-64 Years n=3563 Participants Participants aged 18-64 years were randomized to receive a single dose of seasonal licensed QIV IM per IPM on Day 1.
Percentage of Participants Reporting Any Systemic Events Within 7 Days After Study Vaccination: >=65 Years	58.6 Percentage of participants Interval 57.0 to 60.2	34.9 Percentage of participants Interval 33.3 to 36.4

PRIMARY outcome

Timeframe: From study vaccination on Day 1 through 4 weeks after study vaccination

Population: Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.

An AE was defined as any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention. Results excluded local reactions and systemic events data.

Outcome measures

Outcome measures
Measure	qIRV: 18-64 Years n=9191 Participants Participants aged 18-64 years were randomized to receive a single dose of modRNA qIRV dose level 1 (low) IM on Day 1.	Licensed QIV: 18-64 Years n=9197 Participants Participants aged 18-64 years were randomized to receive a single dose of seasonal licensed QIV IM per IPM on Day 1.
Percentage of Participants Reporting Adverse Events (AEs) From Study Vaccination Through 4 Weeks After Study Vaccination: 18-64 Years	6.7 Percentage of participants Interval 6.2 to 7.3	4.9 Percentage of participants Interval 4.5 to 5.4

PRIMARY outcome

Timeframe: From study vaccination on Day 1 through 4 weeks after study vaccination

Outcome measures

Outcome measures
Measure	qIRV: 18-64 Years n=13557 Participants Participants aged 18-64 years were randomized to receive a single dose of modRNA qIRV dose level 1 (low) IM on Day 1.	Licensed QIV: 18-64 Years n=13611 Participants Participants aged 18-64 years were randomized to receive a single dose of seasonal licensed QIV IM per IPM on Day 1.
Percentage of Participants Reporting AEs From Study Vaccination Through 4 Weeks After Study Vaccination: >=65 Years	8.7 Percentage of participants Interval 8.2 to 9.1	5.9 Percentage of participants Interval 5.5 to 6.3

PRIMARY outcome

Timeframe: From study vaccination on Day 1 through 4 weeks after study vaccination

Population: Analysis population included all participants who received the study intervention. Data was planned to be analyzed in participants aged \>=18 years (combined for 18-64 years and \>65 years) as pre-specified in the protocol. The analysis includes participants who received qIRV at either dose level, as well as QIV.

Outcome measures

Outcome measures
Measure	qIRV: 18-64 Years n=22787 Participants Participants aged 18-64 years were randomized to receive a single dose of modRNA qIRV dose level 1 (low) IM on Day 1.	Licensed QIV: 18-64 Years n=22808 Participants Participants aged 18-64 years were randomized to receive a single dose of seasonal licensed QIV IM per IPM on Day 1.
Percentage of Participants Reporting AEs From Study Vaccination Through 4 Weeks After Study Vaccination: >=18 Years	7.9 Percentage of participants Interval 7.5 to 8.2	5.5 Percentage of participants Interval 5.2 to 5.8

PRIMARY outcome

Timeframe: From Day 1 up to 6 months after vaccination

An SAE was defined as any untoward medical occurrence that, at any dose, met one or more of the following criteria - resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect.

Outcome measures

Outcome measures
Measure	qIRV: 18-64 Years n=9191 Participants Participants aged 18-64 years were randomized to receive a single dose of modRNA qIRV dose level 1 (low) IM on Day 1.	Licensed QIV: 18-64 Years n=9197 Participants Participants aged 18-64 years were randomized to receive a single dose of seasonal licensed QIV IM per IPM on Day 1.
Percentage of Participants Reporting Serious Adverse Events (SAEs) From Study Vaccination Through 6 Months After Study Vaccination: 18-64 Years	0.9 Percentage of participants Interval 0.7 to 1.1	1.0 Percentage of participants Interval 0.8 to 1.2

PRIMARY outcome

Timeframe: From Day 1 up to 6 months after vaccination

Outcome measures

Outcome measures
Measure	qIRV: 18-64 Years n=13557 Participants Participants aged 18-64 years were randomized to receive a single dose of modRNA qIRV dose level 1 (low) IM on Day 1.	Licensed QIV: 18-64 Years n=13611 Participants Participants aged 18-64 years were randomized to receive a single dose of seasonal licensed QIV IM per IPM on Day 1.
Percentage of Participants Reporting SAEs From Study Vaccination Through 6 Months After Study Vaccination: >=65 Years	2.3 Percentage of participants Interval 2.1 to 2.6	2.2 Percentage of participants Interval 1.9 to 2.4

PRIMARY outcome

Timeframe: From Day 1 up to 6 months after vaccination

Outcome measures

Outcome measures
Measure	qIRV: 18-64 Years n=22787 Participants Participants aged 18-64 years were randomized to receive a single dose of modRNA qIRV dose level 1 (low) IM on Day 1.	Licensed QIV: 18-64 Years n=22808 Participants Participants aged 18-64 years were randomized to receive a single dose of seasonal licensed QIV IM per IPM on Day 1.
Percentage of Participants Reporting SAEs From Study Vaccination Through 6 Months After Study Vaccination: >=18 Years	1.8 Percentage of participants Interval 1.6 to 1.9	1.7 Percentage of participants Interval 1.5 to 1.9

SECONDARY outcome

Timeframe: Day 15 to surveillance cut-off (approximately 6 months)

Population: Evaluable efficacy population analyzed.

LCI was defined as influenza infection confirmed through RT-PCR or culture at the central laboratory, unless otherwise specified. Data was obtained during the 2022-2023 northern hemisphere influenza season up to surveillance cut-off decided by Sponsor.

Outcome measures

Outcome measures
Measure	qIRV: 18-64 Years n=9118 Participants Participants aged 18-64 years were randomized to receive a single dose of modRNA qIRV dose level 1 (low) IM on Day 1.	Licensed QIV: 18-64 Years n=9120 Participants Participants aged 18-64 years were randomized to receive a single dose of seasonal licensed QIV IM per IPM on Day 1.
Percentage of Participants Reporting First Episode of LCI Cases With Associated Per-Protocol ILI Caused by All Matched Strains at Least 14 Days After Vaccination: 18-64 Years	0.23 Percentage of participants	0.34 Percentage of participants

SECONDARY outcome

Timeframe: Day 15 up to primary surveillance cut-off (approximately 1 year)

Population: Evaluable efficacy population analyzed.

LCI was defined as influenza infection confirmed through RT-PCR or culture at the central laboratory, unless otherwise specified. Data was obtained during the 2022-2023 northern and southern hemisphere influenza season up to surveillance cut-off decided by Sponsor.

Outcome measures

Outcome measures
Measure	qIRV: 18-64 Years n=13392 Participants Participants aged 18-64 years were randomized to receive a single dose of modRNA qIRV dose level 1 (low) IM on Day 1.	Licensed QIV: 18-64 Years n=13456 Participants Participants aged 18-64 years were randomized to receive a single dose of seasonal licensed QIV IM per IPM on Day 1.
Percentage of Participants Reporting First Episode of LCI Cases With Associated Per-Protocol ILI Caused by All Matched Strains at Least 14 Days After Vaccination: >=65 Years	0.34 Percentage of participants	0.36 Percentage of participants

SECONDARY outcome

Timeframe: Day 15 to surveillance cut-off (approximately 6 months)

Population: Evaluable efficacy population analyzed.

CCI was defined as influenza infection confirmed through culture at the central laboratory, unless otherwise specified. Per-protocol ILI was defined as occurrence (new onset or worsening of preexisting condition) of at least 1 respiratory symptom concurrently with at least 1 systemic symptom. Data was obtained during the 2022-2023 northern hemisphere influenza season up to surveillance cut-off decided by Sponsor.

Outcome measures

Outcome measures
Measure	qIRV: 18-64 Years n=9118 Participants Participants aged 18-64 years were randomized to receive a single dose of modRNA qIRV dose level 1 (low) IM on Day 1.	Licensed QIV: 18-64 Years n=9120 Participants Participants aged 18-64 years were randomized to receive a single dose of seasonal licensed QIV IM per IPM on Day 1.
Percentage of Participants Reporting First Episode of Culture Confirmed Influenza (CCI) With Associated Per-Protocol ILI Caused by Any Strain at Least 14 Days After Vaccination: 18-64 Years	0.23 Percentage of participants	0.34 Percentage of participants

SECONDARY outcome

Timeframe: Day 15 up to primary surveillance cut-off (approximately 1 year)

Population: Evaluable efficacy population analyzed.

CCI was defined as influenza infection confirmed through culture at the central laboratory, unless otherwise specified. Per-protocol ILI was defined as occurrence (new onset or worsening of preexisting condition) of at least 1 respiratory symptom concurrently with at least 1 systemic symptom. Data was obtained during the 2022-2023 northern and southern hemisphere influenza season up to surveillance cut-off decided by Sponsor.

Outcome measures

Outcome measures
Measure	qIRV: 18-64 Years n=13392 Participants Participants aged 18-64 years were randomized to receive a single dose of modRNA qIRV dose level 1 (low) IM on Day 1.	Licensed QIV: 18-64 Years n=13456 Participants Participants aged 18-64 years were randomized to receive a single dose of seasonal licensed QIV IM per IPM on Day 1.
Percentage of Participants Reporting First Episode of CCI With Associated Per-Protocol ILI Caused by Any Strain at Least 14 Days After Vaccination: >=65 Years	0.34 Percentage of participants	0.36 Percentage of participants

SECONDARY outcome

Timeframe: Day 15 to surveillance cut-off (approximately 6 months)

Population: Evaluable efficacy population analyzed.

Outcome measures

Outcome measures
Measure	qIRV: 18-64 Years n=9118 Participants Participants aged 18-64 years were randomized to receive a single dose of modRNA qIRV dose level 1 (low) IM on Day 1.	Licensed QIV: 18-64 Years n=9120 Participants Participants aged 18-64 years were randomized to receive a single dose of seasonal licensed QIV IM per IPM on Day 1.
Percentage of Participants Reporting First Episode of LCI Cases With Associated ILI as Defined by Modified Centers for Disease Control and Prevention (CDC) Caused by Any Strain at Least 14 Days After Vaccination: 18-64 Years	0.46 Percentage of participants	0.61 Percentage of participants

SECONDARY outcome

Timeframe: Day 15 up to primary surveillance cut-off (approximately 1 year)

Population: Evaluable efficacy population analyzed.

LCI was defined as influenza infection confirmed through RT-PCR or culture at the central laboratory, unless otherwise specified. ILI defined modified CDC: occurrence (new onset or worsening of preexisting condition) of at least 1 of the following respiratory symptoms concurrently with an oral temperature \>37.2 deg C (\>99.0 deg F), sore throat or cough. Data was obtained during the 2022-2023 northern and southern hemisphere influenza season up to surveillance cut-off decided by Sponsor.

Outcome measures

Outcome measures
Measure	qIRV: 18-64 Years n=13392 Participants Participants aged 18-64 years were randomized to receive a single dose of modRNA qIRV dose level 1 (low) IM on Day 1.	Licensed QIV: 18-64 Years n=13456 Participants Participants aged 18-64 years were randomized to receive a single dose of seasonal licensed QIV IM per IPM on Day 1.
Percentage of Participants Reporting First Episode of LCI Cases With Associated ILI as Defined by Modified CDC Caused by Any Strain at Least 14 Days After Vaccination: >=65 Years	0.36 Percentage of participants	0.30 Percentage of participants

SECONDARY outcome

Timeframe: Day 15 to surveillance cut-off (approximately 6 months)

Population: Evaluable efficacy population analyzed.

LCI was defined as influenza infection confirmed through RT-PCR or culture at the central laboratory, unless otherwise specified. ILI as per WHO was defined as occurrence (new onset or worsening of preexisting condition) of a cough concurrently with an oral temperature \>=38.0 deg C (\>= 100.4 deg F). Data was obtained during the 2022-2023 northern hemisphere influenza season up to surveillance cut-off decided by Sponsor.

Outcome measures

Outcome measures
Measure	qIRV: 18-64 Years n=9118 Participants Participants aged 18-64 years were randomized to receive a single dose of modRNA qIRV dose level 1 (low) IM on Day 1.	Licensed QIV: 18-64 Years n=9120 Participants Participants aged 18-64 years were randomized to receive a single dose of seasonal licensed QIV IM per IPM on Day 1.
Percentage of Participants Reporting First Episode of LCI Cases With Associated ILI as Defined by World Health Organization (WHO) Caused by Any Strain at Least 14 Days After Vaccination: 18-64 Years	0.27 Percentage of participants	0.35 Percentage of participants

SECONDARY outcome

Timeframe: Day 15 up to primary surveillance cut-off (approximately 1 year)

Population: Evaluable efficacy population analyzed.

LCI was defined as influenza infection confirmed through RT-PCR or culture at the central laboratory, unless otherwise specified. ILI as per WHO was defined as occurrence (new onset or worsening of preexisting condition) of a cough concurrently with an oral temperature \>=38.0 deg C (\>= 100.4 deg F). Data was obtained during the 2022-2023 northern and southern hemisphere influenza season up to surveillance cut-off decided by Sponsor.

Outcome measures

Outcome measures
Measure	qIRV: 18-64 Years n=13392 Participants Participants aged 18-64 years were randomized to receive a single dose of modRNA qIRV dose level 1 (low) IM on Day 1.	Licensed QIV: 18-64 Years n=13456 Participants Participants aged 18-64 years were randomized to receive a single dose of seasonal licensed QIV IM per IPM on Day 1.
Percentage of Participants Reporting First Episode of LCI Cases With Associated ILI as Defined by WHO Caused by Any Strain at Least 14 Days After Vaccination: >=65 Years	0.23 Percentage of participants	0.22 Percentage of participants

SECONDARY outcome

Timeframe: Day 15 to surveillance cut-off (approximately 6 months)

Population: Evaluable efficacy population analyzed.

Per-protocol ILI was defined as occurrence (new onset or worsening of preexisting condition) of at least 1 respiratory symptom concurrently with at least 1 systemic symptom. Data was obtained during the 2022-2023 northern hemisphere influenza season up to surveillance cut-off decided by Sponsor.

Outcome measures

Outcome measures
Measure	qIRV: 18-64 Years n=9118 Participants Participants aged 18-64 years were randomized to receive a single dose of modRNA qIRV dose level 1 (low) IM on Day 1.	Licensed QIV: 18-64 Years n=9120 Participants Participants aged 18-64 years were randomized to receive a single dose of seasonal licensed QIV IM per IPM on Day 1.
Percentage of Participants Reporting First Episode Cases of Influenza as Confirmed by RT-PCR or Local RT-PCR or Culture, With Associated Per-Protocol ILI at Least 14 Days After Vaccination: 18-64 Years	0.66 Percentage of participants	0.98 Percentage of participants

SECONDARY outcome

Timeframe: Day 15 up to primary surveillance cut-off (approximately 1 year)

Population: Evaluable efficacy population analyzed.

Per-protocol ILI was defined as occurrence (new onset or worsening of preexisting condition) of at least 1 respiratory symptom concurrently with at least 1 systemic symptom. Data was obtained during the 2022-2023 northern and southern hemisphere influenza season up to surveillance cut-off decided by Sponsor.

Outcome measures

Outcome measures
Measure	qIRV: 18-64 Years n=13392 Participants Participants aged 18-64 years were randomized to receive a single dose of modRNA qIRV dose level 1 (low) IM on Day 1.	Licensed QIV: 18-64 Years n=13456 Participants Participants aged 18-64 years were randomized to receive a single dose of seasonal licensed QIV IM per IPM on Day 1.
Percentage of Participants Reporting First Episode Cases of Influenza as Confirmed by Central RT-PCR or Local RT-PCR or Culture, With Associated Per-Protocol ILI at Least 14 Days After Vaccination: >=65 Years	0.65 Percentage of participants	0.62 Percentage of participants

SECONDARY outcome

Timeframe: 4 Weeks after vaccination

Population: Evaluable immunogenicity set (Based on HAI Assay 2): eligible participants, received study intervention to which they were randomized, had blood drawn for assay testing within specified time frame, had at least 1 valid, determinate assay result (HAIs determinate assay 2) at 4-week postvaccination, no important protocol deviations. All participants reported under "N" contributed data to table but may not have evaluable data for every row. "n"=number of participants evaluable for specified rows.

Geometric mean titers (GMTs) and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the concentrations and the corresponding CIs (based on the student t distribution) and were reported in the descriptive section. Geometric mean ratios (GMRs) were estimated by the ratio of the GMTs between qIRV recipients compared to licensed QIV recipients vaccine groups and were reported in the statistical analysis section.

Outcome measures

Outcome measures
Measure	qIRV: 18-64 Years n=739 Participants Participants aged 18-64 years were randomized to receive a single dose of modRNA qIRV dose level 1 (low) IM on Day 1.	Licensed QIV: 18-64 Years n=746 Participants Participants aged 18-64 years were randomized to receive a single dose of seasonal licensed QIV IM per IPM on Day 1.
HAI GMTs Used to Determine GMRs of qIRV to Licensed QIV at 4 Weeks After Vaccination for 2022-2023 Northern Hemisphere- Based on HAI Assay 2: 18-64 Years A/H3N2	222.3 Titers Interval 206.0 to 240.0	180.4 Titers Interval 166.6 to 195.4
HAI GMTs Used to Determine GMRs of qIRV to Licensed QIV at 4 Weeks After Vaccination for 2022-2023 Northern Hemisphere- Based on HAI Assay 2: 18-64 Years A/H1N1	397.7 Titers Interval 367.8 to 430.0	321.7 Titers Interval 294.6 to 351.2
HAI GMTs Used to Determine GMRs of qIRV to Licensed QIV at 4 Weeks After Vaccination for 2022-2023 Northern Hemisphere- Based on HAI Assay 2: 18-64 Years B/Yamagata	84.5 Titers Interval 79.4 to 90.0	115.9 Titers Interval 108.5 to 123.8
HAI GMTs Used to Determine GMRs of qIRV to Licensed QIV at 4 Weeks After Vaccination for 2022-2023 Northern Hemisphere- Based on HAI Assay 2: 18-64 Years B/Victoria	21.3 Titers Interval 19.3 to 23.6	70.6 Titers Interval 63.6 to 78.4

SECONDARY outcome

Timeframe: 4 Weeks after vaccination

Population: Evaluable immunogenicity set (Based on HAI Assay 2) analyzed. All participants reported under "Number of Participants Analyzed" contributed data to the table but may not have evaluable data for every row. Here, "Number analyzed" signifies number of participants evaluable for specified rows.

GMTs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the concentrations and the corresponding CIs (based on the student t distribution) and were reported in the descriptive section. GMRs were estimated by the ratio of the GMTs between qIRV recipients compared to licensed QIV recipients vaccine groups and were reported in the statistical analysis section.

Outcome measures

Outcome measures
Measure	qIRV: 18-64 Years n=754 Participants Participants aged 18-64 years were randomized to receive a single dose of modRNA qIRV dose level 1 (low) IM on Day 1.	Licensed QIV: 18-64 Years n=740 Participants Participants aged 18-64 years were randomized to receive a single dose of seasonal licensed QIV IM per IPM on Day 1.
HAI GMTs Used to Determine GMRs of qIRV to Licensed QIV for 2022-2023 Northern Hemisphere at 4 Weeks After Vaccination- Based on HAI Assay 2: >=65 Years A/H3N2	296.0 Titers Interval 273.7 to 320.1	179.8 Titers Interval 166.3 to 194.5
HAI GMTs Used to Determine GMRs of qIRV to Licensed QIV for 2022-2023 Northern Hemisphere at 4 Weeks After Vaccination- Based on HAI Assay 2: >=65 Years A/H1N1	240.0 Titers Interval 220.3 to 261.3	140.6 Titers Interval 129.2 to 152.9
HAI GMTs Used to Determine GMRs of qIRV to Licensed QIV for 2022-2023 Northern Hemisphere at 4 Weeks After Vaccination- Based on HAI Assay 2: >=65 Years B/Yamagata	57.6 Titers Interval 54.1 to 61.2	55.3 Titers Interval 52.0 to 58.9
HAI GMTs Used to Determine GMRs of qIRV to Licensed QIV for 2022-2023 Northern Hemisphere at 4 Weeks After Vaccination- Based on HAI Assay 2: >=65 Years B/Victoria	82.1 Titers Interval 75.0 to 89.9	134.8 Titers Interval 123.5 to 147.3

SECONDARY outcome

Timeframe: 4 Weeks after vaccination

Population: Evaluable immunogenicity set (Based on HAI Assay 2) analyzed. Here, Participants reported under "Number of Participants Analyzed" contributed data but may not be evaluable for every row and "Number Analyzed" signifies number of participants evaluable for specified rows.

Seroconversion was defined as an HAI titer \<1:10 prior to vaccination and \>=1:40 at the time point of interest, or an HAI titer of \>=1:10 prior to vaccination with a 4-fold rise at the time point of interest. Percentage of participants achieving seroconversion for each strain at 4 weeks after vaccination and exact 2-sided 95% CI is presented in the descriptive section. Difference in percentage of participants (qIRV - QIV) achieving HAI seroconversion for each strain at 4 weeks after vaccination is presented in the statistical analysis section.

Outcome measures

Outcome measures
Measure	qIRV: 18-64 Years n=739 Participants Participants aged 18-64 years were randomized to receive a single dose of modRNA qIRV dose level 1 (low) IM on Day 1.	Licensed QIV: 18-64 Years n=746 Participants Participants aged 18-64 years were randomized to receive a single dose of seasonal licensed QIV IM per IPM on Day 1.
Percentage of Participants and Difference in Percentage of Participants Achieving Seroconversion at 4 Weeks After Vaccination With qIRV and Licensed QIV for 2022-2023 Northern Hemisphere- Based on HAI Assay 2: 18-64 Years A/H3N2	64.2 Percentage of Participants Interval 60.6 to 67.7	52.8 Percentage of Participants Interval 49.2 to 56.4
Percentage of Participants and Difference in Percentage of Participants Achieving Seroconversion at 4 Weeks After Vaccination With qIRV and Licensed QIV for 2022-2023 Northern Hemisphere- Based on HAI Assay 2: 18-64 Years A/H1N1	66.1 Percentage of Participants Interval 62.6 to 69.5	52.5 Percentage of Participants Interval 48.8 to 56.1
Percentage of Participants and Difference in Percentage of Participants Achieving Seroconversion at 4 Weeks After Vaccination With qIRV and Licensed QIV for 2022-2023 Northern Hemisphere- Based on HAI Assay 2: 18-64 Years B/Yamagata	13.9 Percentage of Participants Interval 11.4 to 16.6	29.2 Percentage of Participants Interval 26.0 to 32.6
Percentage of Participants and Difference in Percentage of Participants Achieving Seroconversion at 4 Weeks After Vaccination With qIRV and Licensed QIV for 2022-2023 Northern Hemisphere- Based on HAI Assay 2: 18-64 Years B/Victoria	11.4 Percentage of Participants Interval 9.1 to 13.9	51.8 Percentage of Participants Interval 48.2 to 55.5

SECONDARY outcome

Timeframe: 4 Weeks after vaccination

Outcome measures

Outcome measures
Measure	qIRV: 18-64 Years n=754 Participants Participants aged 18-64 years were randomized to receive a single dose of modRNA qIRV dose level 1 (low) IM on Day 1.	Licensed QIV: 18-64 Years n=740 Participants Participants aged 18-64 years were randomized to receive a single dose of seasonal licensed QIV IM per IPM on Day 1.
Percentage of Participants and Difference in Percentage of Participants Achieving Seroconversion at 4 Weeks After Vaccination With qIRV and Licensed QIV for 2022-2023 Northern Hemisphere- Based on HAI Assay 2: >=65 Years A/H3N2	53.2 Percentage of participants Interval 49.6 to 56.8	31.6 Percentage of participants Interval 28.2 to 35.1
Percentage of Participants and Difference in Percentage of Participants Achieving Seroconversion at 4 Weeks After Vaccination With qIRV and Licensed QIV for 2022-2023 Northern Hemisphere- Based on HAI Assay 2: >=65 Years A/H1N1	50.2 Percentage of participants Interval 46.6 to 53.8	24.5 Percentage of participants Interval 21.4 to 27.8
Percentage of Participants and Difference in Percentage of Participants Achieving Seroconversion at 4 Weeks After Vaccination With qIRV and Licensed QIV for 2022-2023 Northern Hemisphere- Based on HAI Assay 2: >=65 Years B/Yamagata	6.4 Percentage of participants Interval 4.8 to 8.4	8.5 Percentage of participants Interval 6.6 to 10.7
Percentage of Participants and Difference in Percentage of Participants Achieving Seroconversion at 4 Weeks After Vaccination With qIRV and Licensed QIV for 2022-2023 Northern Hemisphere- Based on HAI Assay 2: >=65 Years B/Victoria	10.9 Percentage of participants Interval 8.8 to 13.4	33.5 Percentage of participants Interval 30.1 to 37.1

SECONDARY outcome

Timeframe: 4 Weeks after vaccination

Population: Evaluable immunogenicity set (Based on HAI Assay 1) analyzed. Participants reported under "Number of Participants Analyzed" contributed data but may not be evaluable for every row. "Number Analyzed": participants evaluable for rows.

GMTs and 2-sided 95% CIs were reported in the descriptive section. GMRs were estimated by the ratio of the GMTs between qIRV recipients compared to licensed QIV recipients vaccine groups and were reported in the statistical analysis section.

Outcome measures

Outcome measures
Measure	qIRV: 18-64 Years n=1867 Participants Participants aged 18-64 years were randomized to receive a single dose of modRNA qIRV dose level 1 (low) IM on Day 1.	Licensed QIV: 18-64 Years n=1871 Participants Participants aged 18-64 years were randomized to receive a single dose of seasonal licensed QIV IM per IPM on Day 1.
HAI GMTs Used to Determine GMRs of qIRV to Licensed QIV for 2022-2023 Northern Hemisphere at 4 Weeks After Vaccination- Based on HAI Assay 1: 18-64 Years A/H3N2	117.3 Titers Interval 111.2 to 123.6	61.1 Titers Interval 57.8 to 64.5
HAI GMTs Used to Determine GMRs of qIRV to Licensed QIV for 2022-2023 Northern Hemisphere at 4 Weeks After Vaccination- Based on HAI Assay 1: 18-64 Years A/H1N1	203.7 Titers Interval 193.3 to 214.8	121.2 Titers Interval 114.1 to 128.8
HAI GMTs Used to Determine GMRs of qIRV to Licensed QIV for 2022-2023 Northern Hemisphere at 4 Weeks After Vaccination- Based on HAI Assay 1: 18-64 Years B/Yamagata	55.0 Titers Interval 52.6 to 57.5	62.4 Titers Interval 59.4 to 65.5
HAI GMTs Used to Determine GMRs of qIRV to Licensed QIV for 2022-2023 Northern Hemisphere at 4 Weeks After Vaccination- Based on HAI Assay 1: 18-64 Years B/Victoria	16.7 Titers Interval 15.8 to 17.6	28.7 Titers Interval 27.0 to 30.6

SECONDARY outcome

Timeframe: 4 Weeks after vaccination

Outcome measures

Outcome measures
Measure	qIRV: 18-64 Years n=2447 Participants Participants aged 18-64 years were randomized to receive a single dose of modRNA qIRV dose level 1 (low) IM on Day 1.	Licensed QIV: 18-64 Years n=2441 Participants Participants aged 18-64 years were randomized to receive a single dose of seasonal licensed QIV IM per IPM on Day 1.
HAI GMTs Used to Determine GMRs of qIRV to Licensed QIV for 2022-2023 Northern Hemisphere at 4 Weeks After Vaccination - Based on HAI Assay 1: >=65 Years A/H1N1	131.8 Titers Interval 125.9 to 138.0	55.6 Titers Interval 52.8 to 58.5
HAI GMTs Used to Determine GMRs of qIRV to Licensed QIV for 2022-2023 Northern Hemisphere at 4 Weeks After Vaccination - Based on HAI Assay 1: >=65 Years A/H3N2	98.2 Titers Interval 93.9 to 102.8	41.3 Titers Interval 39.4 to 43.3
HAI GMTs Used to Determine GMRs of qIRV to Licensed QIV for 2022-2023 Northern Hemisphere at 4 Weeks After Vaccination - Based on HAI Assay 1: >=65 Years B/Yamagata	38.9 Titers Interval 37.5 to 40.3	28.6 Titers Interval 27.6 to 29.7
HAI GMTs Used to Determine GMRs of qIRV to Licensed QIV for 2022-2023 Northern Hemisphere at 4 Weeks After Vaccination - Based on HAI Assay 1: >=65 Years B/Victoria	40.1 Titers Interval 38.4 to 41.8	52.9 Titers Interval 50.4 to 55.5

SECONDARY outcome

Timeframe: 4 Weeks after vaccination

Outcome measures

Outcome measures
Measure	qIRV: 18-64 Years n=1867 Participants Participants aged 18-64 years were randomized to receive a single dose of modRNA qIRV dose level 1 (low) IM on Day 1.	Licensed QIV: 18-64 Years n=1871 Participants Participants aged 18-64 years were randomized to receive a single dose of seasonal licensed QIV IM per IPM on Day 1.
Percentage of Participants and Difference in Percentage of Participants Achieving Seroconversion at 4 Weeks After Vaccination With qIRV and Licensed QIV for 2022-2023 Northern Hemisphere-Based on HAI Assay 1: 18-64 Years A/H3N2	73.1 Percentage of participants Interval 71.0 to 75.1	46.3 Percentage of participants Interval 44.0 to 48.6
Percentage of Participants and Difference in Percentage of Participants Achieving Seroconversion at 4 Weeks After Vaccination With qIRV and Licensed QIV for 2022-2023 Northern Hemisphere-Based on HAI Assay 1: 18-64 Years A/H1N1	78.3 Percentage of participants Interval 76.4 to 80.2	51.4 Percentage of participants Interval 49.1 to 53.8
Percentage of Participants and Difference in Percentage of Participants Achieving Seroconversion at 4 Weeks After Vaccination With qIRV and Licensed QIV for 2022-2023 Northern Hemisphere-Based on HAI Assay 1: 18-64 Years B/Yamagata	30.0 Percentage of participants Interval 27.9 to 32.1	33.5 Percentage of participants Interval 31.4 to 35.7
Percentage of Participants and Difference in Percentage of Participants Achieving Seroconversion at 4 Weeks After Vaccination With qIRV and Licensed QIV for 2022-2023 Northern Hemisphere-Based on HAI Assay 1: 18-64 Years B/Victoria	13.5 Percentage of participants Interval 12.0 to 15.2	32.7 Percentage of participants Interval 30.6 to 34.9

SECONDARY outcome

Timeframe: 4 Weeks after vaccination

Outcome measures

Outcome measures
Measure	qIRV: 18-64 Years n=2447 Participants Participants aged 18-64 years were randomized to receive a single dose of modRNA qIRV dose level 1 (low) IM on Day 1.	Licensed QIV: 18-64 Years n=2441 Participants Participants aged 18-64 years were randomized to receive a single dose of seasonal licensed QIV IM per IPM on Day 1.
Percentage of Participants and Difference in Percentage of Participants Achieving Seroconversion at 4 Weeks After Vaccination With qIRV and Licensed QIV for 2022-2023 Northern Hemisphere- Based on HAI Assay 1: >=65 Years A/H3N2	66.0 Percentage of participants Interval 64.0 to 67.9	28.1 Percentage of participants Interval 26.3 to 30.0
Percentage of Participants and Difference in Percentage of Participants Achieving Seroconversion at 4 Weeks After Vaccination With qIRV and Licensed QIV for 2022-2023 Northern Hemisphere- Based on HAI Assay 1: >=65 Years A/H1N1	68.4 Percentage of participants Interval 66.5 to 70.3	23.5 Percentage of participants Interval 21.8 to 25.2
Percentage of Participants and Difference in Percentage of Participants Achieving Seroconversion at 4 Weeks After Vaccination With qIRV and Licensed QIV for 2022-2023 Northern Hemisphere- Based on HAI Assay 1: >=65 Years B/Yamagata	22.6 Percentage of participants Interval 21.0 to 24.4	12.0 Percentage of participants Interval 10.7 to 13.4
Percentage of Participants and Difference in Percentage of Participants Achieving Seroconversion at 4 Weeks After Vaccination With qIRV and Licensed QIV for 2022-2023 Northern Hemisphere- Based on HAI Assay 1: >=65 Years B/Victoria	19.8 Percentage of participants Interval 18.2 to 21.4	33.6 Percentage of participants Interval 31.7 to 35.5

SECONDARY outcome

Timeframe: Baseline (Before Vaccination)

Population: Evaluable immunogenicity set (Based on HAI Assay 2) analyzed. Participants reported under "Number of Participants Analyzed" contributed data but may not be evaluable for every row. "Number Analyzed": participants evaluable for rows.

Outcome measures

Outcome measures
Measure	qIRV: 18-64 Years n=739 Participants Participants aged 18-64 years were randomized to receive a single dose of modRNA qIRV dose level 1 (low) IM on Day 1.	Licensed QIV: 18-64 Years n=746 Participants Participants aged 18-64 years were randomized to receive a single dose of seasonal licensed QIV IM per IPM on Day 1.
HAI GMTs at Baseline for the 2022-2023 Northern Hemisphere - Based on HAI Assay 2: 18-64 Years A/H3N2	42.9 Titers Interval 39.7 to 46.3	42.3 Titers Interval 39.3 to 45.4
HAI GMTs at Baseline for the 2022-2023 Northern Hemisphere - Based on HAI Assay 2: 18-64 Years A/H1N1	58.0 Titers Interval 51.8 to 64.9	50.5 Titers Interval 45.2 to 56.4
HAI GMTs at Baseline for the 2022-2023 Northern Hemisphere - Based on HAI Assay 2: 18-64 Years B/Yamagata	49.2 Titers Interval 45.9 to 52.8	46.2 Titers Interval 43.0 to 49.6
HAI GMTs at Baseline for the 2022-2023 Northern Hemisphere - Based on HAI Assay 2: 18-64 Years B/Victoria	13.0 Titers Interval 11.9 to 14.2	13.5 Titers Interval 12.4 to 14.8

SECONDARY outcome

Timeframe: Baseline (Before Vaccination)

Outcome measures

Outcome measures
Measure	qIRV: 18-64 Years n=754 Participants Participants aged 18-64 years were randomized to receive a single dose of modRNA qIRV dose level 1 (low) IM on Day 1.	Licensed QIV: 18-64 Years n=740 Participants Participants aged 18-64 years were randomized to receive a single dose of seasonal licensed QIV IM per IPM on Day 1.
HAI GMTs at Baseline for 2022-2023 Northern Hemisphere - Based on HAI Assay 2: >=65 Years A/H3N2	71.2 Titers Interval 67.1 to 75.6	68.6 Titers Interval 64.7 to 72.7
HAI GMTs at Baseline for 2022-2023 Northern Hemisphere - Based on HAI Assay 2: >=65 Years A/H1N1	60.2 Titers Interval 54.4 to 66.6	58.3 Titers Interval 52.8 to 64.4
HAI GMTs at Baseline for 2022-2023 Northern Hemisphere - Based on HAI Assay 2: >=65 Years B/Yamagata	38.7 Titers Interval 36.5 to 41.1	36.8 Titers Interval 34.5 to 39.2
HAI GMTs at Baseline for 2022-2023 Northern Hemisphere - Based on HAI Assay 2: >=65 Years B/Victoria	47.5 Titers Interval 43.3 to 52.2	43.5 Titers Interval 39.4 to 48.0

SECONDARY outcome

Timeframe: Before vaccination (Baseline) to 4 weeks after vaccination

GMFRs were defined as ratios of the results after vaccination to the results before vaccination (baseline).

Outcome measures

Outcome measures
Measure	qIRV: 18-64 Years n=739 Participants Participants aged 18-64 years were randomized to receive a single dose of modRNA qIRV dose level 1 (low) IM on Day 1.	Licensed QIV: 18-64 Years n=746 Participants Participants aged 18-64 years were randomized to receive a single dose of seasonal licensed QIV IM per IPM on Day 1.
HAI Geometric Mean Fold Rise (GMFR) From Before Vaccination to 4 Weeks After Vaccination for 2022-2023 Northern Hemisphere- Based on HAI Assay 2: 18-64 Years A/H3N2	4.9 Fold rise Interval 4.5 to 5.2	4.1 Fold rise Interval 3.8 to 4.4
HAI Geometric Mean Fold Rise (GMFR) From Before Vaccination to 4 Weeks After Vaccination for 2022-2023 Northern Hemisphere- Based on HAI Assay 2: 18-64 Years A/H1N1	6.0 Fold rise Interval 5.5 to 6.6	5.6 Fold rise Interval 5.0 to 6.2
HAI Geometric Mean Fold Rise (GMFR) From Before Vaccination to 4 Weeks After Vaccination for 2022-2023 Northern Hemisphere- Based on HAI Assay 2: 18-64 Years B/Yamagata	1.7 Fold rise Interval 1.6 to 1.8	2.4 Fold rise Interval 2.2 to 2.5
HAI Geometric Mean Fold Rise (GMFR) From Before Vaccination to 4 Weeks After Vaccination for 2022-2023 Northern Hemisphere- Based on HAI Assay 2: 18-64 Years B/Victoria	1.4 Fold rise Interval 1.4 to 1.5	3.9 Fold rise Interval 3.6 to 4.2

SECONDARY outcome

Timeframe: Before vaccination (Baseline) to 4 weeks after vaccination

GMFRs were defined as ratios of the results after vaccination to the results before vaccination (baseline).

Outcome measures

Outcome measures
Measure	qIRV: 18-64 Years n=754 Participants Participants aged 18-64 years were randomized to receive a single dose of modRNA qIRV dose level 1 (low) IM on Day 1.	Licensed QIV: 18-64 Years n=740 Participants Participants aged 18-64 years were randomized to receive a single dose of seasonal licensed QIV IM per IPM on Day 1.
HAI GMFR Before Vaccination to 4 Weeks After Vaccination for 2022-2023 Northern Hemisphere- Based on HAI Assay 2: >=65 Years A/H3N2	4.2 Fold rise Interval 3.9 to 4.4	2.6 Fold rise Interval 2.5 to 2.8
HAI GMFR Before Vaccination to 4 Weeks After Vaccination for 2022-2023 Northern Hemisphere- Based on HAI Assay 2: >=65 Years A/H1N1	3.7 Fold rise Interval 3.4 to 3.9	2.2 Fold rise Interval 2.0 to 2.4
HAI GMFR Before Vaccination to 4 Weeks After Vaccination for 2022-2023 Northern Hemisphere- Based on HAI Assay 2: >=65 Years B/Yamagata	1.4 Fold rise Interval 1.4 to 1.5	1.4 Fold rise Interval 1.4 to 1.5
HAI GMFR Before Vaccination to 4 Weeks After Vaccination for 2022-2023 Northern Hemisphere- Based on HAI Assay 2: >=65 Years B/Victoria	1.6 Fold rise Interval 1.6 to 1.7	2.8 Fold rise Interval 2.6 to 3.0

SECONDARY outcome

Timeframe: Baseline and 4 weeks after vaccination

Outcome measures

Outcome measures
Measure	qIRV: 18-64 Years n=739 Participants Participants aged 18-64 years were randomized to receive a single dose of modRNA qIRV dose level 1 (low) IM on Day 1.	Licensed QIV: 18-64 Years n=746 Participants Participants aged 18-64 years were randomized to receive a single dose of seasonal licensed QIV IM per IPM on Day 1.
Percentage of Participants With HAI Titers >=1:40 at Baseline and 4 Weeks After Vaccination for 2022-2023 Northern Hemisphere- Based on HAI Assay 2: 18-64 Years Baseline: A/H3N2	65.0 Percentage of participants Interval 61.5 to 68.5	63.1 Percentage of participants Interval 59.6 to 66.6
Percentage of Participants With HAI Titers >=1:40 at Baseline and 4 Weeks After Vaccination for 2022-2023 Northern Hemisphere- Based on HAI Assay 2: 18-64 Years 4 Weeks after vaccination: A/H3N2	99.2 Percentage of participants Interval 98.2 to 99.7	96.5 Percentage of participants Interval 94.9 to 97.7
Percentage of Participants With HAI Titers >=1:40 at Baseline and 4 Weeks After Vaccination for 2022-2023 Northern Hemisphere- Based on HAI Assay 2: 18-64 Years Baseline: A/H1N1	68.0 Percentage of participants Interval 64.5 to 71.4	63.5 Percentage of participants Interval 59.9 to 67.0
Percentage of Participants With HAI Titers >=1:40 at Baseline and 4 Weeks After Vaccination for 2022-2023 Northern Hemisphere- Based on HAI Assay 2: 18-64 Years 4 Weeks after vaccination: A/H1N1	98.4 Percentage of participants Interval 97.2 to 99.2	96.6 Percentage of participants Interval 95.1 to 97.8
Percentage of Participants With HAI Titers >=1:40 at Baseline and 4 Weeks After Vaccination for 2022-2023 Northern Hemisphere- Based on HAI Assay 2: 18-64 Years Baseline: B/Yamagata	71.3 Percentage of participants Interval 67.9 to 74.6	69.3 Percentage of participants Interval 65.9 to 72.6
Percentage of Participants With HAI Titers >=1:40 at Baseline and 4 Weeks After Vaccination for 2022-2023 Northern Hemisphere- Based on HAI Assay 2: 18-64 Years 4 Weeks after vaccination: B/Yamagata	88.7 Percentage of participants Interval 86.2 to 90.9	93.0 Percentage of participants Interval 90.9 to 94.7
Percentage of Participants With HAI Titers >=1:40 at Baseline and 4 Weeks After Vaccination for 2022-2023 Northern Hemisphere- Based on HAI Assay 2: 18-64 Years Baseline: B/Victoria	25.7 Percentage of participants Interval 22.6 to 29.0	24.6 Percentage of participants Interval 21.5 to 27.8
Percentage of Participants With HAI Titers >=1:40 at Baseline and 4 Weeks After Vaccination for 2022-2023 Northern Hemisphere- Based on HAI Assay 2: 18-64 Years 4 Weeks after vaccination: B/Victoria	38.6 Percentage of participants Interval 35.0 to 42.2	72.7 Percentage of participants Interval 69.3 to 75.9

SECONDARY outcome

Timeframe: Baseline and 4 weeks after vaccination

Outcome measures

Outcome measures
Measure	qIRV: 18-64 Years n=754 Participants Participants aged 18-64 years were randomized to receive a single dose of modRNA qIRV dose level 1 (low) IM on Day 1.	Licensed QIV: 18-64 Years n=740 Participants Participants aged 18-64 years were randomized to receive a single dose of seasonal licensed QIV IM per IPM on Day 1.
Percentage of Participants With HAI Titers >=1:40 at Baseline and 4 Weeks After Vaccination for 2022-2023 Northern Hemisphere - Based on HAI Assay 2: >=65 Years Baseline: A/H3N2	84.5 Percentage of participants Interval 81.7 to 87.0	85.6 Percentage of participants Interval 82.8 to 88.0
Percentage of Participants With HAI Titers >=1:40 at Baseline and 4 Weeks After Vaccination for 2022-2023 Northern Hemisphere - Based on HAI Assay 2: >=65 Years 4 Weeks after vaccination: A/H3N2	99.6 Percentage of participants Interval 98.8 to 99.9	97.3 Percentage of participants Interval 95.8 to 98.3
Percentage of Participants With HAI Titers >=1:40 at Baseline and 4 Weeks After Vaccination for 2022-2023 Northern Hemisphere - Based on HAI Assay 2: >=65 Years Baseline: A/H1N1	70.5 Percentage of participants Interval 67.1 to 73.7	73.2 Percentage of participants Interval 69.8 to 76.4
Percentage of Participants With HAI Titers >=1:40 at Baseline and 4 Weeks After Vaccination for 2022-2023 Northern Hemisphere - Based on HAI Assay 2: >=65 Years 4 Weeks after vaccination: A/H1N1	96.2 Percentage of participants Interval 94.5 to 97.4	92.1 Percentage of participants Interval 89.9 to 93.9
Percentage of Participants With HAI Titers >=1:40 at Baseline and 4 Weeks After Vaccination for 2022-2023 Northern Hemisphere - Based on HAI Assay 2: >=65 Years Baseline: B/Yamagata	60.9 Percentage of participants Interval 57.3 to 64.4	60.7 Percentage of participants Interval 57.1 to 64.3
Percentage of Participants With HAI Titers >=1:40 at Baseline and 4 Weeks After Vaccination for 2022-2023 Northern Hemisphere - Based on HAI Assay 2: >=65 Years 4 Weeks after vaccination: B/Yamagata	77.3 Percentage of participants Interval 74.1 to 80.3	75.0 Percentage of participants Interval 71.7 to 78.1
Percentage of Participants With HAI Titers >=1:40 at Baseline and 4 Weeks After Vaccination for 2022-2023 Northern Hemisphere - Based on HAI Assay 2: >=65 Years Baseline: B/Victoria	64.4 Percentage of participants Interval 60.9 to 67.9	61.6 Percentage of participants Interval 57.9 to 65.1
Percentage of Participants With HAI Titers >=1:40 at Baseline and 4 Weeks After Vaccination for 2022-2023 Northern Hemisphere - Based on HAI Assay 2: >=65 Years 4 Weeks after vaccination: B/Victoria	78.7 Percentage of participants Interval 75.6 to 81.5	89.8 Percentage of participants Interval 87.4 to 91.9

SECONDARY outcome

Timeframe: Baseline

Outcome measures

Outcome measures
Measure	qIRV: 18-64 Years n=1867 Participants Participants aged 18-64 years were randomized to receive a single dose of modRNA qIRV dose level 1 (low) IM on Day 1.	Licensed QIV: 18-64 Years n=1871 Participants Participants aged 18-64 years were randomized to receive a single dose of seasonal licensed QIV IM per IPM on Day 1.
HAI GMTs at Baseline for 2022-2023 Northern Hemisphere - Based on HAI Assay 1: 18-64 Years B/Yamagata	22.7 Titers Interval 21.6 to 23.8	22.7 Titers Interval 21.6 to 23.9
HAI GMTs at Baseline for 2022-2023 Northern Hemisphere - Based on HAI Assay 1: 18-64 Years A/H3N2	18.2 Titers Interval 17.3 to 19.2	17.6 Titers Interval 16.7 to 18.5
HAI GMTs at Baseline for 2022-2023 Northern Hemisphere - Based on HAI Assay 1: 18-64 Years A/H1N1	22.7 Titers Interval 21.4 to 24.1	23.1 Titers Interval 21.8 to 24.5
HAI GMTs at Baseline for 2022-2023 Northern Hemisphere - Based on HAI Assay 1: 18-64 Years B/Victoria	10.1 Titers Interval 9.6 to 10.6	10.1 Titers Interval 9.6 to 10.5

SECONDARY outcome

Timeframe: Baseline

Outcome measures

Outcome measures
Measure	qIRV: 18-64 Years n=2447 Participants Participants aged 18-64 years were randomized to receive a single dose of modRNA qIRV dose level 1 (low) IM on Day 1.	Licensed QIV: 18-64 Years n=2441 Participants Participants aged 18-64 years were randomized to receive a single dose of seasonal licensed QIV IM per IPM on Day 1.
HAI GMTs at Baseline for 2022-2023 Northern Hemisphere- Based on HAI Assay 1: >=65 Years A/H3N2	19.7 Titers Interval 18.9 to 20.6	19.0 Titers Interval 18.2 to 19.8
HAI GMTs at Baseline for 2022-2023 Northern Hemisphere- Based on HAI Assay 1: >=65 Years A/H1N1	25.2 Titers Interval 24.0 to 26.4	24.5 Titers Interval 23.4 to 25.8
HAI GMTs at Baseline for 2022-2023 Northern Hemisphere- Based on HAI Assay 1: >=65 Years B/Yamagata	18.1 Titers Interval 17.4 to 18.7	17.2 Titers Interval 16.6 to 17.8
HAI GMTs at Baseline for 2022-2023 Northern Hemisphere- Based on HAI Assay 1: >=65 Years B/Victoria	20.0 Titers Interval 19.1 to 20.9	19.7 Titers Interval 18.8 to 20.6

SECONDARY outcome

Timeframe: Before vaccination (Baseline) to 4 weeks after vaccination

GMFRs were defined as ratios of the results after vaccination to the results before vaccination (baseline).

Outcome measures

Outcome measures
Measure	qIRV: 18-64 Years n=1867 Participants Participants aged 18-64 years were randomized to receive a single dose of modRNA qIRV dose level 1 (low) IM on Day 1.	Licensed QIV: 18-64 Years n=1871 Participants Participants aged 18-64 years were randomized to receive a single dose of seasonal licensed QIV IM per IPM on Day 1.
HAI GMFR Before Vaccination to 4 Weeks After Vaccination for 2022-2023 Northern Hemisphere- Based on HAI Assay 1: 18-64 Years A/H3N2	5.4 Fold rise Interval 5.1 to 5.6	2.9 Fold rise Interval 2.8 to 3.1
HAI GMFR Before Vaccination to 4 Weeks After Vaccination for 2022-2023 Northern Hemisphere- Based on HAI Assay 1: 18-64 Years A/H1N1	7.5 Fold rise Interval 7.1 to 7.9	4.4 Fold rise Interval 4.1 to 4.7
HAI GMFR Before Vaccination to 4 Weeks After Vaccination for 2022-2023 Northern Hemisphere- Based on HAI Assay 1: 18-64 Years B/Yamagata	2.2 Fold rise Interval 2.1 to 2.2	2.4 Fold rise Interval 2.3 to 2.5
HAI GMFR Before Vaccination to 4 Weeks After Vaccination for 2022-2023 Northern Hemisphere- Based on HAI Assay 1: 18-64 Years B/Victoria	1.4 Fold rise Interval 1.4 to 1.5	2.2 Fold rise Interval 2.1 to 2.3

SECONDARY outcome

Timeframe: Before vaccination (Baseline) to 4 weeks after vaccination

GMFRs were defined as ratios of the results after vaccination to the results before vaccination.

Outcome measures

Outcome measures
Measure	qIRV: 18-64 Years n=2447 Participants Participants aged 18-64 years were randomized to receive a single dose of modRNA qIRV dose level 1 (low) IM on Day 1.	Licensed QIV: 18-64 Years n=2441 Participants Participants aged 18-64 years were randomized to receive a single dose of seasonal licensed QIV IM per IPM on Day 1.
HAI GMFR Before Vaccination to 4 Weeks After Vaccination for 2022-2023 Northern Hemisphere- Based on HAI Assay 1: >=65 Years A/H3N2	4.2 Fold rise Interval 4.1 to 4.4	1.9 Fold rise Interval 1.9 to 2.0
HAI GMFR Before Vaccination to 4 Weeks After Vaccination for 2022-2023 Northern Hemisphere- Based on HAI Assay 1: >=65 Years A/H1N1	4.5 Fold rise Interval 4.4 to 4.7	2.0 Fold rise Interval 1.9 to 2.1
HAI GMFR Before Vaccination to 4 Weeks After Vaccination for 2022-2023 Northern Hemisphere- Based on HAI Assay 1: >=65 Years B/Yamagata	1.9 Fold rise Interval 1.9 to 2.0	1.5 Fold rise Interval 1.5 to 1.5
HAI GMFR Before Vaccination to 4 Weeks After Vaccination for 2022-2023 Northern Hemisphere- Based on HAI Assay 1: >=65 Years B/Victoria	1.8 Fold rise Interval 1.8 to 1.9	2.4 Fold rise Interval 2.3 to 2.5

SECONDARY outcome

Timeframe: Baseline and 4 weeks after vaccination

Outcome measures

Outcome measures
Measure	qIRV: 18-64 Years n=1867 Participants Participants aged 18-64 years were randomized to receive a single dose of modRNA qIRV dose level 1 (low) IM on Day 1.	Licensed QIV: 18-64 Years n=1871 Participants Participants aged 18-64 years were randomized to receive a single dose of seasonal licensed QIV IM per IPM on Day 1.
Percentage of Participants With HAI Titers >=1:40 at Baseline and 4 Weeks After Vaccination for 2022-2023 Northern Hemisphere - Based on HAI Assay 1: 18-64 Years Baseline: A/H3N2	36.8 Percentage of participants Interval 34.6 to 39.1	35.2 Percentage of participants Interval 33.0 to 37.4
Percentage of Participants With HAI Titers >=1:40 at Baseline and 4 Weeks After Vaccination for 2022-2023 Northern Hemisphere - Based on HAI Assay 1: 18-64 Years 4 Weeks after vaccination: A/H3N2	91.1 Percentage of participants Interval 89.7 to 92.4	75.8 Percentage of participants Interval 73.7 to 77.7
Percentage of Participants With HAI Titers >=1:40 at Baseline and 4 Weeks After Vaccination for 2022-2023 Northern Hemisphere - Based on HAI Assay 1: 18-64 Years Baseline: A/H1N1	41.6 Percentage of participants Interval 39.4 to 43.9	44.9 Percentage of participants Interval 42.7 to 47.3
Percentage of Participants With HAI Titers >=1:40 at Baseline and 4 Weeks After Vaccination for 2022-2023 Northern Hemisphere - Based on HAI Assay 1: 18-64 Years 4 Weeks after vaccination: A/H1N1	95.0 Percentage of participants Interval 93.9 to 95.9	86.8 Percentage of participants Interval 85.2 to 88.3
Percentage of Participants With HAI Titers >=1:40 at Baseline and 4 Weeks After Vaccination for 2022-2023 Northern Hemisphere - Based on HAI Assay 1: 18-64 Years Baseline: B/Yamagata	42.2 Percentage of participants Interval 40.0 to 44.5	43.0 Percentage of participants Interval 40.7 to 45.3
Percentage of Participants With HAI Titers >=1:40 at Baseline and 4 Weeks After Vaccination for 2022-2023 Northern Hemisphere - Based on HAI Assay 1: 18-64 Years 4 Weeks after vaccination: B/Yamagata	75.3 Percentage of participants Interval 73.2 to 77.2	76.7 Percentage of participants Interval 74.7 to 78.6
Percentage of Participants With HAI Titers >=1:40 at Baseline and 4 Weeks After Vaccination for 2022-2023 Northern Hemisphere - Based on HAI Assay 1: 18-64 Years Baseline: B/Victoria	16.3 Percentage of participants Interval 14.6 to 18.1	15.5 Percentage of participants Interval 13.8 to 17.2
Percentage of Participants With HAI Titers >=1:40 at Baseline and 4 Weeks After Vaccination for 2022-2023 Northern Hemisphere - Based on HAI Assay 1: 18-64 Years 4 Weeks after vaccination: B/Victoria	31.9 Percentage of participants Interval 29.8 to 34.1	47.0 Percentage of participants Interval 44.7 to 49.3

SECONDARY outcome

Timeframe: Baseline and 4 weeks after vaccination

Outcome measures

Outcome measures
Measure	qIRV: 18-64 Years n=2447 Participants Participants aged 18-64 years were randomized to receive a single dose of modRNA qIRV dose level 1 (low) IM on Day 1.	Licensed QIV: 18-64 Years n=2441 Participants Participants aged 18-64 years were randomized to receive a single dose of seasonal licensed QIV IM per IPM on Day 1.
Percentage of Participants With HAI Titers >=1:40 at Baseline and 4 Weeks After Vaccination for 2022-2023 Northern Hemisphere - Based on HAI Assay 1: >=65 Years Baseline: A/H3N2	40.4 Percentage of participants Interval 38.4 to 42.4	37.6 Percentage of participants Interval 35.6 to 39.6
Percentage of Participants With HAI Titers >=1:40 at Baseline and 4 Weeks After Vaccination for 2022-2023 Northern Hemisphere - Based on HAI Assay 1: >=65 Years 4 Weeks after vaccination: A/H3N2	88.3 Percentage of participants Interval 87.0 to 89.6	64.6 Percentage of participants Interval 62.7 to 66.5
Percentage of Participants With HAI Titers >=1:40 at Baseline and 4 Weeks After Vaccination for 2022-2023 Northern Hemisphere - Based on HAI Assay 1: >=65 Years Baseline: A/H1N1	46.4 Percentage of participants Interval 44.4 to 48.5	44.4 Percentage of participants Interval 42.4 to 46.4
Percentage of Participants With HAI Titers >=1:40 at Baseline and 4 Weeks After Vaccination for 2022-2023 Northern Hemisphere - Based on HAI Assay 1: >=65 Years 4 Weeks after vaccination: A/H1N1	91.7 Percentage of participants Interval 90.6 to 92.8	70.6 Percentage of participants Interval 68.8 to 72.4
Percentage of Participants With HAI Titers >=1:40 at Baseline and 4 Weeks After Vaccination for 2022-2023 Northern Hemisphere - Based on HAI Assay 1: >=65 Years Baseline: B/Yamagata	31.0 Percentage of participants Interval 29.1 to 32.9	28.3 Percentage of participants Interval 26.5 to 30.2
Percentage of Participants With HAI Titers >=1:40 at Baseline and 4 Weeks After Vaccination for 2022-2023 Northern Hemisphere - Based on HAI Assay 1: >=65 Years 4 Weeks after vaccination: B/Yamagata	65.1 Percentage of participants Interval 63.2 to 67.0	50.2 Percentage of participants Interval 48.2 to 52.2
Percentage of Participants With HAI Titers >=1:40 at Baseline and 4 Weeks After Vaccination for 2022-2023 Northern Hemisphere - Based on HAI Assay 1: >=65 Years Baseline: B/Victoria	36.3 Percentage of participants Interval 34.3 to 38.3	35.2 Percentage of participants Interval 33.2 to 37.1
Percentage of Participants With HAI Titers >=1:40 at Baseline and 4 Weeks After Vaccination for 2022-2023 Northern Hemisphere - Based on HAI Assay 1: >=65 Years 4 Weeks after vaccination: B/Victoria	63.6 Percentage of participants Interval 61.7 to 65.5	69.0 Percentage of participants Interval 67.1 to 70.8

SECONDARY outcome

Timeframe: Baseline and 4 weeks after vaccination

Population: As there was no participant from southern hemisphere aged 18-64 years, no data was collected for this outcome measure. Therefore, there was no analysis performed for this outcome measure.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Baseline and 4 weeks after vaccination

Outcome measures

Outcome measures
Measure	qIRV: 18-64 Years n=391 Participants Participants aged 18-64 years were randomized to receive a single dose of modRNA qIRV dose level 1 (low) IM on Day 1.	Licensed QIV: 18-64 Years n=390 Participants Participants aged 18-64 years were randomized to receive a single dose of seasonal licensed QIV IM per IPM on Day 1.
HAI GMTs at Baseline and 4 Weeks After Vaccination for 2023 Southern Hemisphere - Based on HAI Assay 2: >=65 Years 4 Weeks after vaccination: A/H1N1	73.8 Titers Interval 62.9 to 86.5	92.7 Titers Interval 80.0 to 107.4
HAI GMTs at Baseline and 4 Weeks After Vaccination for 2023 Southern Hemisphere - Based on HAI Assay 2: >=65 Years Baseline: A/H3N2	84.1 Titers Interval 77.1 to 91.8	82.9 Titers Interval 76.1 to 90.2
HAI GMTs at Baseline and 4 Weeks After Vaccination for 2023 Southern Hemisphere - Based on HAI Assay 2: >=65 Years 4 Weeks after vaccination: A/H3N2	460.9 Titers Interval 414.8 to 512.0	272.2 Titers Interval 244.3 to 303.3
HAI GMTs at Baseline and 4 Weeks After Vaccination for 2023 Southern Hemisphere - Based on HAI Assay 2: >=65 Years Baseline: A/H1N1	10.9 Titers Interval 9.7 to 12.3	12.2 Titers Interval 10.8 to 13.8
HAI GMTs at Baseline and 4 Weeks After Vaccination for 2023 Southern Hemisphere - Based on HAI Assay 2: >=65 Years Baseline: B/Yamagata	35.5 Titers Interval 32.1 to 39.2	37.5 Titers Interval 33.8 to 41.5
HAI GMTs at Baseline and 4 Weeks After Vaccination for 2023 Southern Hemisphere - Based on HAI Assay 2: >=65 Years 4 Weeks after vaccination: B/Yamagata	70.0 Titers Interval 64.0 to 76.5	81.4 Titers Interval 74.5 to 88.9
HAI GMTs at Baseline and 4 Weeks After Vaccination for 2023 Southern Hemisphere - Based on HAI Assay 2: >=65 Years Baseline: B/Victoria	34.0 Titers Interval 29.6 to 39.2	31.1 Titers Interval 26.9 to 36.0
HAI GMTs at Baseline and 4 Weeks After Vaccination for 2023 Southern Hemisphere - Based on HAI Assay 2: >=65 Years 4 Weeks after vaccination: B/Victoria	77.9 Titers Interval 69.1 to 87.8	124.2 Titers Interval 109.9 to 140.5

SECONDARY outcome

Timeframe: Before vaccination (Baseline) to 4 weeks after vaccination

Population: As there was no participant from southern hemisphere aged 18-64 years, no data was collected for this outcome measure. Therefore, there was no analysis performed for this outcome measure.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Before vaccination (Baseline) to 4 weeks after vaccination

GMFRs were defined as ratios of the results after vaccination to the results before vaccination (baseline).

Outcome measures

Outcome measures
Measure	qIRV: 18-64 Years n=391 Participants Participants aged 18-64 years were randomized to receive a single dose of modRNA qIRV dose level 1 (low) IM on Day 1.	Licensed QIV: 18-64 Years n=390 Participants Participants aged 18-64 years were randomized to receive a single dose of seasonal licensed QIV IM per IPM on Day 1.
HAI GMFR Before Vaccination to 4 Weeks After Vaccination for 2023 Southern Hemisphere- Based on HAI Assay 2: >=65 Years A/H3N2	5.5 Fold rise Interval 5.0 to 6.0	3.3 Fold rise Interval 3.0 to 3.6
HAI GMFR Before Vaccination to 4 Weeks After Vaccination for 2023 Southern Hemisphere- Based on HAI Assay 2: >=65 Years A/H1N1	4.8 Fold rise Interval 4.2 to 5.4	5.4 Fold rise Interval 4.7 to 6.2
HAI GMFR Before Vaccination to 4 Weeks After Vaccination for 2023 Southern Hemisphere- Based on HAI Assay 2: >=65 Years B/Yamagata	1.8 Fold rise Interval 1.7 to 2.0	2.0 Fold rise Interval 1.9 to 2.2
HAI GMFR Before Vaccination to 4 Weeks After Vaccination for 2023 Southern Hemisphere- Based on HAI Assay 2: >=65 Years B/Victoria	2.0 Fold rise Interval 1.9 to 2.2	3.3 Fold rise Interval 3.0 to 3.8

SECONDARY outcome

Timeframe: 4 weeks after vaccination

Population: As there was no participant from southern hemisphere aged 18-64 years, no data was collected for this outcome measure. Therefore, there was no analysis performed for this outcome measure.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: 4 weeks after vaccination

Outcome measures

Outcome measures
Measure	qIRV: 18-64 Years n=391 Participants Participants aged 18-64 years were randomized to receive a single dose of modRNA qIRV dose level 1 (low) IM on Day 1.	Licensed QIV: 18-64 Years n=390 Participants Participants aged 18-64 years were randomized to receive a single dose of seasonal licensed QIV IM per IPM on Day 1.
Percentage of Participants Achieving HAI Seroconversion at 4 Weeks After Vaccination for 2023 Southern Hemisphere- Based on HAI Assay 2: >=65 Years A/H3N2	68.9 Percentage of participants Interval 64.0 to 73.5	41.6 Percentage of participants Interval 36.6 to 46.7
Percentage of Participants Achieving HAI Seroconversion at 4 Weeks After Vaccination for 2023 Southern Hemisphere- Based on HAI Assay 2: >=65 Years A/H1N1	58.5 Percentage of participants Interval 53.4 to 63.5	58.7 Percentage of participants Interval 53.6 to 63.7
Percentage of Participants Achieving HAI Seroconversion at 4 Weeks After Vaccination for 2023 Southern Hemisphere- Based on HAI Assay 2: >=65 Years B/Yamagata	16.3 Percentage of participants Interval 12.8 to 20.4	21.6 Percentage of participants Interval 17.6 to 26.0
Percentage of Participants Achieving HAI Seroconversion at 4 Weeks After Vaccination for 2023 Southern Hemisphere- Based on HAI Assay 2: >=65 Years B/Victoria	21.0 Percentage of participants Interval 17.1 to 25.5	36.4 Percentage of participants Interval 31.6 to 41.5

SECONDARY outcome

Timeframe: Baseline and 4 weeks after vaccination

Population: As there was no participant from southern hemisphere aged 18-64 years, no data was collected for this outcome measure. Therefore, there was no analysis performed for this outcome measure.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Baseline and 4 weeks after vaccination

Outcome measures

Outcome measures
Measure	qIRV: 18-64 Years n=391 Participants Participants aged 18-64 years were randomized to receive a single dose of modRNA qIRV dose level 1 (low) IM on Day 1.	Licensed QIV: 18-64 Years n=390 Participants Participants aged 18-64 years were randomized to receive a single dose of seasonal licensed QIV IM per IPM on Day 1.
Percentage of Participants With HAI Titers >=1:40 at Baseline and 4 Weeks After Vaccination for 2023 Southern Hemisphere - Based on HAI Assay 2: >=65 Years Baseline: A/H3N2	93.8 Percentage of participants Interval 90.9 to 96.0	94.0 Percentage of participants Interval 91.2 to 96.2
Percentage of Participants With HAI Titers >=1:40 at Baseline and 4 Weeks After Vaccination for 2023 Southern Hemisphere - Based on HAI Assay 2: >=65 Years 4 weeks after vaccination: A/H3N2	100.0 Percentage of participants Interval 99.1 to 100.0	99.0 Percentage of participants Interval 97.4 to 99.7
Percentage of Participants With HAI Titers >=1:40 at Baseline and 4 Weeks After Vaccination for 2023 Southern Hemisphere - Based on HAI Assay 2: >=65 Years Baseline: A/H1N1	19.8 Percentage of participants Interval 16.0 to 24.2	23.6 Percentage of participants Interval 19.4 to 28.1
Percentage of Participants With HAI Titers >=1:40 at Baseline and 4 Weeks After Vaccination for 2023 Southern Hemisphere - Based on HAI Assay 2: >=65 Years 4 weeks after vaccination: A/H1N1	70.0 Percentage of participants Interval 65.2 to 74.5	76.6 Percentage of participants Interval 72.1 to 80.7
Percentage of Participants With HAI Titers >=1:40 at Baseline and 4 Weeks After Vaccination for 2023 Southern Hemisphere - Based on HAI Assay 2: >=65 Years Baseline: B/Yamagata	56.5 Percentage of participants Interval 51.4 to 61.5	61.0 Percentage of participants Interval 56.0 to 65.9
Percentage of Participants With HAI Titers >=1:40 at Baseline and 4 Weeks After Vaccination for 2023 Southern Hemisphere - Based on HAI Assay 2: >=65 Years 4 weeks after vaccination: B/Yamagata	82.9 Percentage of participants Interval 78.8 to 86.6	87.4 Percentage of participants Interval 83.7 to 90.5
Percentage of Participants With HAI Titers >=1:40 at Baseline and 4 Weeks After Vaccination for 2023 Southern Hemisphere - Based on HAI Assay 2: >=65 Years Baseline: B/Victoria	54.8 Percentage of participants Interval 49.7 to 59.9	50.8 Percentage of participants Interval 45.7 to 55.9
Percentage of Participants With HAI Titers >=1:40 at Baseline and 4 Weeks After Vaccination for 2023 Southern Hemisphere - Based on HAI Assay 2: >=65 Years 4 weeks after vaccination: B/Victoria	80.8 Percentage of participants Interval 76.5 to 84.6	86.9 Percentage of participants Interval 83.1 to 90.1

SECONDARY outcome

Timeframe: Baseline and 4 weeks after vaccination

Population: As there was no participant from southern hemisphere aged 18-64 years, no data was collected for this outcome measure. Therefore, there was no analysis performed for this outcome measure.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Baseline and 4 weeks after vaccination

Outcome measures

Outcome measures
Measure	qIRV: 18-64 Years n=391 Participants Participants aged 18-64 years were randomized to receive a single dose of modRNA qIRV dose level 1 (low) IM on Day 1.	Licensed QIV: 18-64 Years n=390 Participants Participants aged 18-64 years were randomized to receive a single dose of seasonal licensed QIV IM per IPM on Day 1.
HAI GMTs at Baseline and 4 Weeks After Vaccination for 2023 Southern Hemisphere - Based on HAI Assay 1: >=65 Years Baseline: A/H3N2	32.9 Titers Interval 29.7 to 36.5	30.4 Titers Interval 27.4 to 33.7
HAI GMTs at Baseline and 4 Weeks After Vaccination for 2023 Southern Hemisphere - Based on HAI Assay 1: >=65 Years 4 Weeks after vaccination: A/H3N2	224.0 Titers Interval 199.2 to 252.0	96.8 Titers Interval 86.2 to 108.7
HAI GMTs at Baseline and 4 Weeks After Vaccination for 2023 Southern Hemisphere - Based on HAI Assay 1: >=65 Years Baseline: A/H1N1	14.8 Titers Interval 13.1 to 16.7	15.0 Titers Interval 13.3 to 17.0
HAI GMTs at Baseline and 4 Weeks After Vaccination for 2023 Southern Hemisphere - Based on HAI Assay 1: >=65 Years 4 Weeks after vaccination: A/H1N1	129.5 Titers Interval 111.9 to 149.9	88.0 Titers Interval 76.3 to 101.3
HAI GMTs at Baseline and 4 Weeks After Vaccination for 2023 Southern Hemisphere - Based on HAI Assay 1: >=65 Years Baseline: B/Yamagata	16.1 Titers Interval 14.7 to 17.6	16.1 Titers Interval 14.7 to 17.6
HAI GMTs at Baseline and 4 Weeks After Vaccination for 2023 Southern Hemisphere - Based on HAI Assay 1: >=65 Years 4 Weeks after vaccination: B/Yamagata	40.4 Titers Interval 37.2 to 43.7	38.0 Titers Interval 34.6 to 41.9
HAI GMTs at Baseline and 4 Weeks After Vaccination for 2023 Southern Hemisphere - Based on HAI Assay 1: >=65 Years Baseline: B/Victoria	20.4 Titers Interval 18.3 to 22.9	19.6 Titers Interval 17.5 to 22.0
HAI GMTs at Baseline and 4 Weeks After Vaccination for 2023 Southern Hemisphere - Based on HAI Assay 1: >=65 Years 4 Weeks after vaccination: B/Victoria	45.9 Titers Interval 41.3 to 51.1	55.6 Titers Interval 49.6 to 62.4

SECONDARY outcome

Timeframe: Before Vaccination (baseline) to 4 weeks after vaccination

Population: As there was no participant from southern hemisphere aged 18-64 years, no data was collected for this outcome measure. Therefore, there was no analysis performed for this outcome measure.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Before vaccination (baseline) to 4 weeks after vaccination

GMFRs were defined as ratios of the results after vaccination to the results before vaccination (baseline).

Outcome measures

Outcome measures
Measure	qIRV: 18-64 Years n=391 Participants Participants aged 18-64 years were randomized to receive a single dose of modRNA qIRV dose level 1 (low) IM on Day 1.	Licensed QIV: 18-64 Years n=390 Participants Participants aged 18-64 years were randomized to receive a single dose of seasonal licensed QIV IM per IPM on Day 1.
HAI GMFR Before Vaccination to 4 Weeks After Vaccination for the 2023 Southern Hemisphere - Based on HAI Assay 1: >=65 Years A/H3N2	6.4 Fold rise Interval 5.8 to 7.1	3.0 Fold rise Interval 2.7 to 3.3
HAI GMFR Before Vaccination to 4 Weeks After Vaccination for the 2023 Southern Hemisphere - Based on HAI Assay 1: >=65 Years A/H1N1	6.8 Fold rise Interval 6.0 to 7.6	4.5 Fold rise Interval 4.0 to 5.1
HAI GMFR Before Vaccination to 4 Weeks After Vaccination for the 2023 Southern Hemisphere - Based on HAI Assay 1: >=65 Years B/Yamagata	2.2 Fold rise Interval 2.1 to 2.3	2.1 Fold rise Interval 1.9 to 2.3
HAI GMFR Before Vaccination to 4 Weeks After Vaccination for the 2023 Southern Hemisphere - Based on HAI Assay 1: >=65 Years B/Victoria	2.0 Fold rise Interval 1.8 to 2.1	2.5 Fold rise Interval 2.3 to 2.7

SECONDARY outcome

Timeframe: 4 weeks after vaccination

Population: As there was no participant from southern hemisphere aged 18-64 years, no data was collected for this outcome measure. Therefore, there was no analysis performed for this outcome measure.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: 4 weeks after vaccination

Outcome measures

Outcome measures
Measure	qIRV: 18-64 Years n=391 Participants Participants aged 18-64 years were randomized to receive a single dose of modRNA qIRV dose level 1 (low) IM on Day 1.	Licensed QIV: 18-64 Years n=390 Participants Participants aged 18-64 years were randomized to receive a single dose of seasonal licensed QIV IM per IPM on Day 1.
Percentage of Participants Achieving HAI Seroconversion at 4 Weeks After Vaccination for 2023 Southern Hemisphere - Based on HAI Assay 1: >=65 Years A/H3N2	81.7 Percentage of participants Interval 77.4 to 85.4	44.9 Percentage of participants Interval 39.8 to 50.0
Percentage of Participants Achieving HAI Seroconversion at 4 Weeks After Vaccination for 2023 Southern Hemisphere - Based on HAI Assay 1: >=65 Years A/H1N1	77.2 Percentage of participants Interval 72.7 to 81.3	57.9 Percentage of participants Interval 52.9 to 62.9
Percentage of Participants Achieving HAI Seroconversion at 4 Weeks After Vaccination for 2023 Southern Hemisphere - Based on HAI Assay 1: >=65 Years B/Yamagata	29.8 Percentage of participants Interval 25.3 to 34.6	28.8 Percentage of participants Interval 24.3 to 33.6
Percentage of Participants Achieving HAI Seroconversion at 4 Weeks After Vaccination for 2023 Southern Hemisphere - Based on HAI Assay 1: >=65 Years B/Victoria	23.5 Percentage of participants Interval 19.3 to 28.0	36.9 Percentage of participants Interval 32.1 to 41.9

SECONDARY outcome

Timeframe: Baseline and 4 weeks after vaccination

Population: As there was no participant from southern hemisphere aged 18-64 years, no data was collected for this outcome measure. Therefore, there was no analysis performed for this outcome measure.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Baseline and 4 weeks after vaccination

Outcome measures

Outcome measures
Measure	qIRV: 18-64 Years n=391 Participants Participants aged 18-64 years were randomized to receive a single dose of modRNA qIRV dose level 1 (low) IM on Day 1.	Licensed QIV: 18-64 Years n=390 Participants Participants aged 18-64 years were randomized to receive a single dose of seasonal licensed QIV IM per IPM on Day 1.
Percentage of Participants With HAI Titers >=1:40 at Baseline and 4 Weeks After Vaccination for 2023 Southern Hemisphere - Based on HAI Assay 1: >=65 Years 4 weeks after vaccination: A/H3N2	98.2 Percentage of participants Interval 96.3 to 99.3	89.8 Percentage of participants Interval 86.3 to 92.6
Percentage of Participants With HAI Titers >=1:40 at Baseline and 4 Weeks After Vaccination for 2023 Southern Hemisphere - Based on HAI Assay 1: >=65 Years Baseline: A/H3N2	61.3 Percentage of participants Interval 56.2 to 66.2	58.3 Percentage of participants Interval 53.1 to 63.3
Percentage of Participants With HAI Titers >=1:40 at Baseline and 4 Weeks After Vaccination for 2023 Southern Hemisphere - Based on HAI Assay 1: >=65 Years Baseline: A/H1N1	27.9 Percentage of participants Interval 23.5 to 32.7	28.5 Percentage of participants Interval 24.0 to 33.2
Percentage of Participants With HAI Titers >=1:40 at Baseline and 4 Weeks After Vaccination for 2023 Southern Hemisphere - Based on HAI Assay 1: >=65 Years 4 weeks after vaccination: A/H1N1	85.6 Percentage of participants Interval 81.8 to 89.0	77.9 Percentage of participants Interval 73.5 to 82.0
Percentage of Participants With HAI Titers >=1:40 at Baseline and 4 Weeks After Vaccination for 2023 Southern Hemisphere - Based on HAI Assay 1: >=65 Years Baseline: B/Yamagata	28.5 Percentage of participants Interval 24.1 to 33.3	26.7 Percentage of participants Interval 22.3 to 31.4
Percentage of Participants With HAI Titers >=1:40 at Baseline and 4 Weeks After Vaccination for 2023 Southern Hemisphere - Based on HAI Assay 1: >=65 Years 4 weeks after vaccination: B/Yamagata	69.4 Percentage of participants Interval 64.6 to 74.0	61.9 Percentage of participants Interval 56.9 to 66.8
Percentage of Participants With HAI Titers >=1:40 at Baseline and 4 Weeks After Vaccination for 2023 Southern Hemisphere - Based on HAI Assay 1: >=65 Years Baseline: B/Victoria	38.1 Percentage of participants Interval 33.3 to 43.2	34.6 Percentage of participants Interval 29.9 to 39.6
Percentage of Participants With HAI Titers >=1:40 at Baseline and 4 Weeks After Vaccination for 2023 Southern Hemisphere - Based on HAI Assay 1: >=65 Years 4 weeks after vaccination: B/Victoria	69.3 Percentage of participants Interval 64.5 to 73.9	73.8 Percentage of participants Interval 69.2 to 78.1

Adverse Events

qIRV: 18-64 Years

Serious events: 83 serious events

Other events: 2607 other events

Deaths: 7 deaths

Licensed QIV: 18-64 Years

Serious events: 93 serious events

Other events: 1964 other events

Deaths: 9 deaths

qIRV: >=65 Years

Serious events: 318 serious events

Other events: 3091 other events

Deaths: 49 deaths

Licensed QIV: >=65 Years

Serious events: 296 serious events

Other events: 1720 other events

Deaths: 46 deaths

qIRV (>=18 Years)

Serious events: 401 serious events

Other events: 5698 other events

Deaths: 56 deaths

Licensed QIV: >=18 Years

Serious events: 389 serious events

Other events: 3684 other events

Deaths: 55 deaths

Serious adverse events

Serious adverse events
Measure	qIRV: 18-64 Years n=9191 participants at risk Participants aged 18-64 years were randomized to receive a single dose of modRNA qIRV dose level 1 (low) IM on Day 1.	Licensed QIV: 18-64 Years n=9197 participants at risk Participants aged 18-64 years were randomized to receive a single dose of seasonal licensed QIV IM per IPM on Day 1.	qIRV: >=65 Years n=13557 participants at risk Participants aged \>=65 years were randomized to receive a single dose of qIRV dose level 2 (high) IM on Day 1.	Licensed QIV: >=65 Years n=13611 participants at risk Participants aged \>=65 years were randomized to receive a single dose of seasonal licensed QIV IM per IPM on Day 1.	qIRV (>=18 Years) n=22787 participants at risk Participants aged \>=18 years were randomized to receive a single dose of qIRV dose level 1 (low) and dose level 2 (high) IM on Day 1.	Licensed QIV: >=18 Years n=22808 participants at risk Participants aged \>=18 years were randomized to receive a single dose of seasonal licensed QIV IM per IPM on Day 1.
Blood and lymphatic system disorders Anaemia	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.03% 4/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.02% 4/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Blood and lymphatic system disorders Blood loss anaemia	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Blood and lymphatic system disorders Iron deficiency anaemia	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Blood and lymphatic system disorders Monoclonal B-cell lymphocytosis	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Blood and lymphatic system disorders Thrombocytopenia	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Cardiac disorders Acute coronary syndrome	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.02% 3/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 3/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Cardiac disorders Acute myocardial infarction	0.01% 1/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.02% 2/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.04% 6/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.07% 10/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.03% 7/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.05% 12/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Cardiac disorders Angina pectoris	0.01% 1/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Cardiac disorders Angina unstable	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Cardiac disorders Aortic valve disease	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Cardiac disorders Arrhythmia	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Cardiac disorders Arteriosclerosis coronary artery	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.02% 3/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 3/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Cardiac disorders Atrial fibrillation	0.02% 2/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.15% 21/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.11% 15/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.10% 23/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.07% 16/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Cardiac disorders Atrial flutter	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Cardiac disorders Atrioventricular block complete	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Cardiac disorders Atrioventricular block second degree	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.02% 3/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 3/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Cardiac disorders Bradycardia	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Cardiac disorders Bundle branch block right	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Cardiac disorders Cardiac aneurysm	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Cardiac disorders Cardiac arrest	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.02% 2/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.06% 8/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.02% 3/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.04% 8/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.02% 5/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Cardiac disorders Cardiac failure	0.01% 1/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.02% 3/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.02% 4/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Cardiac disorders Cardiac failure acute	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.02% 3/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 3/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Cardiac disorders Cardiac failure congestive	0.02% 2/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.02% 2/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.07% 10/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.10% 13/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.05% 12/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.07% 15/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Cardiac disorders Cardio-respiratory arrest	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.03% 4/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.04% 5/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.02% 4/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.03% 6/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Cardiac disorders Cardiogenic shock	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Cardiac disorders Cardiomyopathy	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Cardiac disorders Cardiopulmonary failure	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Cardiac disorders Chronic left ventricular failure	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Cardiac disorders Cor pulmonale	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Cardiac disorders Coronary artery disease	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.07% 9/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.05% 7/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.04% 9/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.03% 7/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Cardiac disorders Coronary artery occlusion	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Cardiac disorders Coronary artery stenosis	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Cardiac disorders Diastolic dysfunction	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Cardiac disorders Dilated cardiomyopathy	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Cardiac disorders Hypertensive heart disease	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.02% 3/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 3/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Cardiac disorders Ischaemic cardiomyopathy	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Cardiac disorders Left ventricular failure	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Cardiac disorders Left ventricular hypertrophy	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Cardiac disorders Mitral valve incompetence	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Cardiac disorders Mitral valve prolapse	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Cardiac disorders Myocardial infarction	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.03% 3/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.06% 8/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.05% 7/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.04% 8/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.04% 10/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Cardiac disorders Myocardial ischaemia	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Cardiac disorders Palpitations	0.01% 1/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Cardiac disorders Pericardial effusion	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Cardiac disorders Pericarditis	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Cardiac disorders Right ventricular failure	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Cardiac disorders Supraventricular tachycardia	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.02% 3/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.02% 4/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Cardiac disorders Tachycardia	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Cardiac disorders Tricuspid valve incompetence	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Cardiac disorders Trifascicular block	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Cardiac disorders Ventricular arrhythmia	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Cardiac disorders Ventricular extrasystoles	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Cardiac disorders Ventricular fibrillation	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Cardiac disorders Ventricular tachycardia	0.01% 1/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.02% 3/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.02% 4/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Congenital, familial and genetic disorders Hypertrophic cardiomyopathy	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Ear and labyrinth disorders Meniere's disease	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Ear and labyrinth disorders Middle ear disorder	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Ear and labyrinth disorders Vertigo	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Ear and labyrinth disorders Vertigo positional	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Endocrine disorders Cushing's syndrome	0.01% 1/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Endocrine disorders Hypothyroidism	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Eye disorders Glaucoma	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Eye disorders Vision blurred	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Gastrointestinal disorders Abdominal hernia	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Gastrointestinal disorders Abdominal pain	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Gastrointestinal disorders Abdominal wall haematoma	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Gastrointestinal disorders Anogenital dysplasia	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Gastrointestinal disorders Barrett's oesophagus	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Gastrointestinal disorders Colitis	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Gastrointestinal disorders Colitis ischaemic	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Gastrointestinal disorders Colitis microscopic	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Gastrointestinal disorders Colitis ulcerative	0.01% 1/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Gastrointestinal disorders Diarrhoea	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Gastrointestinal disorders Duodenal ulcer haemorrhage	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Gastrointestinal disorders Duodenal ulcer perforation	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Gastrointestinal disorders Dysphagia	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Gastrointestinal disorders Faecaloma	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Gastrointestinal disorders Food poisoning	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Gastrointestinal disorders Gastric ulcer haemorrhage	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Gastrointestinal disorders Gastritis	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Gastrointestinal disorders Gastrointestinal disorder	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Gastrointestinal disorders Gastrointestinal haemorrhage	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Gastrointestinal disorders Gastrooesophageal reflux disease	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Gastrointestinal disorders Haemorrhoidal haemorrhage	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Gastrointestinal disorders Hiatus hernia	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Gastrointestinal disorders Ileal perforation	0.01% 1/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Gastrointestinal disorders Inguinal hernia	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Gastrointestinal disorders Intestinal obstruction	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.02% 3/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 3/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Gastrointestinal disorders Intestinal perforation	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Gastrointestinal disorders Intra-abdominal haemorrhage	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Gastrointestinal disorders Large intestinal stenosis	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Gastrointestinal disorders Large intestine perforation	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Gastrointestinal disorders Nausea	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Gastrointestinal disorders Obstructive pancreatitis	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Gastrointestinal disorders Oesophageal food impaction	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Gastrointestinal disorders Pancreatitis	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Gastrointestinal disorders Pancreatitis acute	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.02% 2/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.02% 3/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.02% 3/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 3/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.02% 5/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Gastrointestinal disorders Peptic ulcer	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Gastrointestinal disorders Peptic ulcer perforation	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Gastrointestinal disorders Rectal haemorrhage	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Gastrointestinal disorders Retroperitoneal effusion	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Gastrointestinal disorders Small intestinal obstruction	0.01% 1/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.02% 3/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.02% 4/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Gastrointestinal disorders Upper gastrointestinal haemorrhage	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Gastrointestinal disorders Varices oesophageal	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Gastrointestinal disorders Vomiting	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
General disorders Asthenia	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
General disorders Chest pain	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.07% 9/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.04% 9/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
General disorders Death	0.02% 2/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.04% 6/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.02% 3/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.04% 8/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 3/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
General disorders Multi-organ disorder	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
General disorders Multiple organ dysfunction syndrome	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.03% 4/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.02% 4/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
General disorders Non-cardiac chest pain	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
General disorders Oedema peripheral	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
General disorders Organ failure	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
General disorders Sudden cardiac death	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
General disorders Vaccination site reaction	0.01% 1/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
General disorders Vascular stent stenosis	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Hepatobiliary disorders Biliary dyskinesia	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Hepatobiliary disorders Biliary obstruction	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Hepatobiliary disorders Cholecystitis	0.02% 2/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.02% 4/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Hepatobiliary disorders Cholecystitis acute	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 3/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Hepatobiliary disorders Cholelithiasis	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.02% 3/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.04% 5/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 3/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.02% 5/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Hepatobiliary disorders Hepatic cirrhosis	0.01% 1/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Hepatobiliary disorders Hepatitis acute	0.01% 1/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Hepatobiliary disorders Hypertransaminasaemia	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Hepatobiliary disorders Jaundice cholestatic	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Immune system disorders Anaphylactic reaction	0.01% 1/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 3/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Immune system disorders Anti-neutrophil cytoplasmic antibody positive vasculitis	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Infections and infestations Abdominal abscess	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Infections and infestations Abdominal wall abscess	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Infections and infestations Abscess limb	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Infections and infestations Amoebic dysentery	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Infections and infestations Appendicitis	0.04% 4/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.02% 2/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.03% 6/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 3/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Infections and infestations Appendicitis perforated	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Infections and infestations Arthritis bacterial	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Infections and infestations Bacteraemia	0.01% 1/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Infections and infestations Bronchitis	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Infections and infestations COVID-19	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.03% 4/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.02% 4/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 3/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Infections and infestations COVID-19 pneumonia	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.02% 3/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 3/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Infections and infestations Cellulitis	0.01% 1/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.03% 3/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.04% 5/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.04% 6/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.03% 6/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.04% 9/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Infections and infestations Cholecystitis infective	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Infections and infestations Clostridium difficile colitis	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Infections and infestations Clostridium difficile infection	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Infections and infestations Cystitis	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Infections and infestations Diabetic foot infection	0.01% 1/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Infections and infestations Diverticulitis	0.02% 2/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.02% 2/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.03% 4/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.03% 6/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.02% 4/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Infections and infestations Diverticulitis intestinal haemorrhagic	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Infections and infestations Enterococcal bacteraemia	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Infections and infestations Fungaemia	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Infections and infestations Gangrene	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Infections and infestations Gastroenteritis	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.02% 3/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 3/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Infections and infestations Gastroenteritis bacterial	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Infections and infestations Gastroenteritis viral	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Infections and infestations Gastrointestinal infection	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.02% 3/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 3/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Infections and infestations Haematoma infection	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Infections and infestations Haemophilus bacteraemia	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Infections and infestations Herpes zoster	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Infections and infestations Infected skin ulcer	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Infections and infestations Infection	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Infections and infestations Infective tenosynovitis	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Infections and infestations Influenza	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Infections and infestations Kidney infection	0.02% 2/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Infections and infestations Localised infection	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Infections and infestations Lower respiratory tract infection	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Infections and infestations Meningitis	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Infections and infestations Osteomyelitis	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.02% 3/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 3/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Infections and infestations Parainfluenzae virus infection	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Infections and infestations Peritonitis	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Infections and infestations Pharyngitis streptococcal	0.01% 1/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Infections and infestations Pneumonia	0.08% 7/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.08% 7/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.18% 25/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.18% 25/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.14% 32/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.14% 32/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Infections and infestations Pneumonia bacterial	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Infections and infestations Pneumonia pneumococcal	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Infections and infestations Pneumonia streptococcal	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Infections and infestations Pneumonia viral	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Infections and infestations Post procedural infection	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Infections and infestations Post procedural sepsis	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Infections and infestations Post-acute COVID-19 syndrome	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Infections and infestations Postoperative wound infection	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Infections and infestations Pulmonary sepsis	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Infections and infestations Pulmonary tuberculosis	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Infections and infestations Pyelonephritis	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.02% 3/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 3/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Infections and infestations Pyelonephritis acute	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Infections and infestations Respiratory syncytial virus infection	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Infections and infestations Rhinovirus infection	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Infections and infestations Sepsis	0.02% 2/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.02% 2/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.07% 9/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.06% 8/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.05% 11/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.04% 10/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Infections and infestations Septic arthritis staphylococcal	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Infections and infestations Septic shock	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.04% 6/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.05% 7/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.03% 6/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.03% 7/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Infections and infestations Staphylococcal bacteraemia	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Infections and infestations Submandibular abscess	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Infections and infestations Upper respiratory tract infection	0.01% 1/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.02% 2/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 3/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Infections and infestations Urinary tract infection	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.05% 7/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.03% 7/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Infections and infestations Urosepsis	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Infections and infestations Vascular device infection	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Infections and infestations Viral infection	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Infections and infestations Wound infection	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Injury, poisoning and procedural complications Alcohol poisoning	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Injury, poisoning and procedural complications Anaemia postoperative	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Injury, poisoning and procedural complications Animal bite	0.01% 1/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Injury, poisoning and procedural complications Ankle fracture	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Injury, poisoning and procedural complications Arthropod sting	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Injury, poisoning and procedural complications Brain herniation	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Injury, poisoning and procedural complications Carbon monoxide poisoning	0.01% 1/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Injury, poisoning and procedural complications Cartilage injury	0.01% 1/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Injury, poisoning and procedural complications Cervical vertebral fracture	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Injury, poisoning and procedural complications Concussion	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Injury, poisoning and procedural complications Contusion	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Injury, poisoning and procedural complications Craniocerebral injury	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Injury, poisoning and procedural complications Craniofacial fracture	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Injury, poisoning and procedural complications Dislocation of vertebra	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Injury, poisoning and procedural complications Dural tear	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Injury, poisoning and procedural complications Extradural haematoma	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Injury, poisoning and procedural complications Face injury	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Injury, poisoning and procedural complications Fall	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.04% 5/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.02% 5/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Injury, poisoning and procedural complications Femoral neck fracture	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Injury, poisoning and procedural complications Femur fracture	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.03% 4/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.02% 3/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.02% 4/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 3/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Injury, poisoning and procedural complications Fibula fracture	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Injury, poisoning and procedural complications Foot fracture	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Injury, poisoning and procedural complications Gastrointestinal procedural complication	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Injury, poisoning and procedural complications Gun shot wound	0.01% 1/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Injury, poisoning and procedural complications Head injury	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Injury, poisoning and procedural complications Hip fracture	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.04% 5/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.02% 3/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.02% 5/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 3/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Injury, poisoning and procedural complications Humerus fracture	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Injury, poisoning and procedural complications Injury	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Injury, poisoning and procedural complications Intentional overdose	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Injury, poisoning and procedural complications Joint injury	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Injury, poisoning and procedural complications Ligament sprain	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Injury, poisoning and procedural complications Multiple fractures	0.01% 1/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Injury, poisoning and procedural complications Multiple injuries	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Injury, poisoning and procedural complications Overdose	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Injury, poisoning and procedural complications Patella fracture	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Injury, poisoning and procedural complications Pelvic fracture	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Injury, poisoning and procedural complications Periprosthetic fracture	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Injury, poisoning and procedural complications Post procedural complication	0.01% 1/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Injury, poisoning and procedural complications Procedural complication	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Injury, poisoning and procedural complications Procedural pain	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Injury, poisoning and procedural complications Rib fracture	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Injury, poisoning and procedural complications Road traffic accident	0.01% 1/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Injury, poisoning and procedural complications Skin laceration	0.01% 1/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Injury, poisoning and procedural complications Skull fracture	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Injury, poisoning and procedural complications Spinal cord injury cervical	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Injury, poisoning and procedural complications Spinal fracture	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Injury, poisoning and procedural complications Stab wound	0.01% 1/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Injury, poisoning and procedural complications Sternal fracture	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Injury, poisoning and procedural complications Subdural haematoma	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Injury, poisoning and procedural complications Subdural haemorrhage	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Injury, poisoning and procedural complications Thermal burn	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Injury, poisoning and procedural complications Thoracic vertebral fracture	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Injury, poisoning and procedural complications Tibia fracture	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Injury, poisoning and procedural complications Toxicity to various agents	0.01% 1/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Injury, poisoning and procedural complications Traumatic haemothorax	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Injury, poisoning and procedural complications Upper limb fracture	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Injury, poisoning and procedural complications Vaginal cuff dehiscence	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Injury, poisoning and procedural complications Wound dehiscence	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Injury, poisoning and procedural complications Wrist fracture	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Investigations Blood glucose increased	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Investigations Hepatic enzyme increased	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Investigations Human rhinovirus test positive	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Investigations SARS-CoV-2 test positive	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Metabolism and nutrition disorders Dehydration	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.04% 6/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.03% 6/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Metabolism and nutrition disorders Diabetic complication	0.01% 1/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Metabolism and nutrition disorders Diabetic ketoacidosis	0.01% 1/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Metabolism and nutrition disorders Diabetic metabolic decompensation	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Metabolism and nutrition disorders Electrolyte imbalance	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Metabolism and nutrition disorders Gout	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Metabolism and nutrition disorders Hypercalcaemia	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Metabolism and nutrition disorders Hyperglycaemia	0.01% 1/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Metabolism and nutrition disorders Hyperkalaemia	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Metabolism and nutrition disorders Hypervolaemia	0.01% 1/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Metabolism and nutrition disorders Hypoglycaemia	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.04% 5/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.02% 5/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Metabolism and nutrition disorders Hypokalaemia	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Metabolism and nutrition disorders Hyponatraemia	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.03% 4/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.02% 4/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Metabolism and nutrition disorders Lactic acidosis	0.01% 1/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Metabolism and nutrition disorders Type 2 diabetes mellitus	0.01% 1/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 3/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Musculoskeletal and connective tissue disorders Arthralgia	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.02% 3/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 3/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 3/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Musculoskeletal and connective tissue disorders Arthritis	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Musculoskeletal and connective tissue disorders Back pain	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Musculoskeletal and connective tissue disorders Cervical spinal stenosis	0.01% 1/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Musculoskeletal and connective tissue disorders Fasciitis	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Musculoskeletal and connective tissue disorders Groin pain	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Musculoskeletal and connective tissue disorders Haemarthrosis	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Musculoskeletal and connective tissue disorders Intervertebral disc degeneration	0.01% 1/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Musculoskeletal and connective tissue disorders Intervertebral disc protrusion	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Musculoskeletal and connective tissue disorders Lumbar spinal stenosis	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Musculoskeletal and connective tissue disorders Muscle spasms	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Musculoskeletal and connective tissue disorders Musculoskeletal pain	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Musculoskeletal and connective tissue disorders Osteoarthritis	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.02% 2/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.03% 4/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.02% 4/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 3/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Musculoskeletal and connective tissue disorders Pain in extremity	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Musculoskeletal and connective tissue disorders Pathological fracture	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Musculoskeletal and connective tissue disorders Polymyalgia rheumatica	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Musculoskeletal and connective tissue disorders Pseudarthrosis	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Musculoskeletal and connective tissue disorders Rhabdomyolysis	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Musculoskeletal and connective tissue disorders Rotator cuff syndrome	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Acute myeloid leukaemia	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Adenocarcinoma	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Adenocarcinoma of colon	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Anal squamous cell carcinoma	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Basal cell carcinoma	0.01% 1/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Bladder cancer	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Breast cancer	0.01% 1/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.04% 6/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.03% 4/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.03% 7/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.02% 5/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Breast cancer metastatic	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Cholangiocarcinoma	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Colon cancer	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Endometrial adenocarcinoma	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Endometrial cancer	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Gallbladder adenocarcinoma	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Gallbladder cancer metastatic	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Glioblastoma	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Hepatic cancer	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Hepatic cancer recurrent	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Hepatobiliary cancer	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Hepatocellular carcinoma	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Intraductal proliferative breast lesion	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Invasive ductal breast carcinoma	0.01% 1/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Invasive lobular breast carcinoma	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Liposarcoma	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Lung cancer metastatic	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Lung carcinoma cell type unspecified stage III	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Lung carcinoma cell type unspecified stage IV	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Lung neoplasm malignant	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Lymphoma	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Malignant melanoma	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Meningioma	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Metastases to bone	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Metastases to liver	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Metastases to lymph nodes	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Metastases to pleura	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Metastatic bronchial carcinoma	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Metastatic uterine cancer	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Mueller's mixed tumour	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Neoplasm malignant	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Neuroendocrine carcinoma of the bladder	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Ocular lymphoma	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Oesophageal carcinoma	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Ovarian cancer	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Ovarian cancer metastatic	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Pancreatic carcinoma	0.01% 1/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Papillary thyroid cancer	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Plasma cell myeloma	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 3/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Prostate cancer	0.02% 2/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.03% 4/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.04% 5/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.03% 6/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.02% 5/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Prostate cancer metastatic	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Renal cancer	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Small cell lung cancer	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Squamous cell carcinoma of the tongue	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Throat cancer	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Thyroid cancer	0.01% 1/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Urinary tract neoplasm	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Uterine cancer	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Uterine leiomyoma	0.01% 1/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Nervous system disorders Aphasia	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Nervous system disorders Axonal and demyelinating polyneuropathy	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Nervous system disorders Basal ganglia infarction	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Nervous system disorders Brain stem stroke	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Nervous system disorders Carotid artery stenosis	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Nervous system disorders Cauda equina syndrome	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Nervous system disorders Cerebral haemorrhage	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Nervous system disorders Cerebral infarction	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Nervous system disorders Cerebrovascular accident	0.01% 1/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.06% 8/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.07% 9/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.04% 9/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.04% 9/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Nervous system disorders Cervical radiculopathy	0.01% 1/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Nervous system disorders Dizziness	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Nervous system disorders Embolic stroke	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Nervous system disorders Encephalopathy	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Nervous system disorders Haemorrhagic stroke	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.02% 3/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 3/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Nervous system disorders Headache	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Nervous system disorders Hypoaesthesia	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 3/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Nervous system disorders Idiopathic intracranial hypertension	0.01% 1/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Nervous system disorders Intracranial aneurysm	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Nervous system disorders Ischaemic stroke	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.03% 4/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.03% 4/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.02% 4/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.02% 4/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Nervous system disorders Lacunar infarction	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Nervous system disorders Loss of consciousness	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Nervous system disorders Metabolic encephalopathy	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Nervous system disorders Migraine	0.01% 1/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Nervous system disorders Myasthenia gravis	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Nervous system disorders Myelin oligodendrocyte glycoprotein antibody-associated disease	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Nervous system disorders Nervous system disorder	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Nervous system disorders Neuropathy peripheral	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Nervous system disorders Ophthalmic migraine	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Nervous system disorders Paraplegia	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Nervous system disorders Parkinson's disease	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Nervous system disorders Partial seizures	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Nervous system disorders Presyncope	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Nervous system disorders Sciatica	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Nervous system disorders Seizure	0.02% 2/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.02% 3/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.02% 5/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Nervous system disorders Status epilepticus	0.01% 1/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Nervous system disorders Subarachnoid haemorrhage	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.02% 3/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.02% 4/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Nervous system disorders Syncope	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.03% 3/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.03% 4/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.02% 3/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.02% 4/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.03% 6/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Nervous system disorders Toxic encephalopathy	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Nervous system disorders Transient ischaemic attack	0.01% 1/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.04% 6/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.04% 5/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.03% 7/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.02% 5/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Pregnancy, puerperium and perinatal conditions Abortion spontaneous	0.02% 2/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.02% 2/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Pregnancy, puerperium and perinatal conditions Anembryonic gestation	0.01% 1/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Product Issues Device dislocation	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Product Issues Device inappropriate shock delivery	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Product Issues Device issue	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Product Issues Device occlusion	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Psychiatric disorders Alcohol abuse	0.01% 1/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Psychiatric disorders Alcohol withdrawal syndrome	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Psychiatric disorders Anxiety	0.01% 1/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Psychiatric disorders Bipolar disorder	0.01% 1/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Psychiatric disorders Completed suicide	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Psychiatric disorders Confusional state	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Psychiatric disorders Depression	0.02% 2/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.02% 2/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 3/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Psychiatric disorders Drug abuse	0.01% 1/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Psychiatric disorders Dysphemia	0.01% 1/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Psychiatric disorders Major depression	0.02% 2/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Psychiatric disorders Mania	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Psychiatric disorders Mental disorder	0.01% 1/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Psychiatric disorders Mental status changes	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Psychiatric disorders Post-traumatic stress disorder	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Psychiatric disorders Suicidal ideation	0.01% 1/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Renal and urinary disorders Acute kidney injury	0.01% 1/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.12% 16/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.05% 7/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.07% 17/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.04% 8/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Renal and urinary disorders Chronic kidney disease	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.03% 4/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.02% 4/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Renal and urinary disorders Diabetic nephropathy	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Renal and urinary disorders End stage renal disease	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Renal and urinary disorders Glomerulonephritis rapidly progressive	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Renal and urinary disorders Nephrolithiasis	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.02% 3/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.02% 3/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 3/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 3/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Renal and urinary disorders Nephrosclerosis	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Renal and urinary disorders Renal mass	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Renal and urinary disorders Renal tubular injury	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Renal and urinary disorders Urinary retention	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.03% 4/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.02% 4/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Renal and urinary disorders Urinary tract obstruction	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Reproductive system and breast disorders Benign prostatic hyperplasia	0.01% 1/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Reproductive system and breast disorders Ovarian cyst ruptured	0.01% 1/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Reproductive system and breast disorders Ovarian mass	0.01% 1/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Reproductive system and breast disorders Prostatitis	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Reproductive system and breast disorders Uterine prolapse	0.01% 1/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Reproductive system and breast disorders Vaginal prolapse	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Respiratory, thoracic and mediastinal disorders Acute respiratory distress syndrome	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.02% 3/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 3/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Respiratory, thoracic and mediastinal disorders Acute respiratory failure	0.01% 1/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.02% 2/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.13% 17/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.04% 6/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.08% 18/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.04% 8/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Respiratory, thoracic and mediastinal disorders Asthma	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.02% 3/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 3/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 3/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Respiratory, thoracic and mediastinal disorders Asthma-chronic obstructive pulmonary disease overlap syndrome	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Respiratory, thoracic and mediastinal disorders Bronchial disorder	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Respiratory, thoracic and mediastinal disorders Bronchiectasis	0.01% 1/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Respiratory, thoracic and mediastinal disorders Chronic obstructive pulmonary disease	0.02% 2/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.03% 3/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.07% 10/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.09% 12/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.05% 12/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.07% 15/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Respiratory, thoracic and mediastinal disorders Dyspnoea	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Respiratory, thoracic and mediastinal disorders Haemoptysis	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Respiratory, thoracic and mediastinal disorders Haemothorax	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Respiratory, thoracic and mediastinal disorders Hypoxia	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.02% 3/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 3/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 3/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Respiratory, thoracic and mediastinal disorders Laryngeal mass	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Respiratory, thoracic and mediastinal disorders Pharyngeal haematoma	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Respiratory, thoracic and mediastinal disorders Pleural effusion	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.03% 4/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.03% 4/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.02% 4/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.02% 5/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Respiratory, thoracic and mediastinal disorders Pneumonitis aspiration	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Respiratory, thoracic and mediastinal disorders Pneumothorax	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Respiratory, thoracic and mediastinal disorders Pulmonary embolism	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.05% 7/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.04% 5/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.03% 7/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.02% 5/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Respiratory, thoracic and mediastinal disorders Pulmonary hypertension	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.02% 3/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 3/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Respiratory, thoracic and mediastinal disorders Pulmonary mass	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Respiratory, thoracic and mediastinal disorders Pulmonary oedema	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Respiratory, thoracic and mediastinal disorders Pulmonary thrombosis	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Respiratory, thoracic and mediastinal disorders Respiratory disorder	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Respiratory, thoracic and mediastinal disorders Respiratory distress	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Respiratory, thoracic and mediastinal disorders Respiratory failure	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.02% 2/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.03% 4/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.03% 6/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Respiratory, thoracic and mediastinal disorders Sleep apnoea syndrome	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Respiratory, thoracic and mediastinal disorders Wheezing	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Skin and subcutaneous tissue disorders Angioedema	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Skin and subcutaneous tissue disorders Drug reaction with eosinophilia and systemic symptoms	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Skin and subcutaneous tissue disorders Ecchymosis	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Skin and subcutaneous tissue disorders Skin ulcer	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Social circumstances Substance use	0.01% 1/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Surgical and medical procedures Hospitalisation	0.01% 1/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Vascular disorders Aortic aneurysm	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Vascular disorders Aortic aneurysm rupture	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Vascular disorders Aortic arteriosclerosis	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Vascular disorders Aortic dilatation	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Vascular disorders Aortic dissection	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Vascular disorders Aortic embolus	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Vascular disorders Aortic intramural haematoma	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Vascular disorders Aortic stenosis	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Vascular disorders Aortic thrombosis	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Vascular disorders Arteriosclerosis	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Vascular disorders Cyanosis	0.01% 1/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Vascular disorders Deep vein thrombosis	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Vascular disorders Haematoma	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Vascular disorders Hypertension	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Vascular disorders Hypertensive crisis	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Vascular disorders Hypertensive emergency	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Vascular disorders Hypertensive urgency	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Vascular disorders Hypotension	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Vascular disorders Hypovolaemic shock	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Vascular disorders Intermittent claudication	0.01% 1/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Vascular disorders Internal haemorrhage	0.01% 1/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Vascular disorders Lymphoedema	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Vascular disorders Necrosis ischaemic	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Vascular disorders Penetrating atherosclerotic ulcer	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Vascular disorders Peripheral arterial occlusive disease	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Vascular disorders Peripheral artery occlusion	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 2/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Vascular disorders Peripheral ischaemia	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Vascular disorders Peripheral vascular disorder	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Vascular disorders Peripheral venous disease	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Vascular disorders Scalp haematoma	0.00% 0/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.01% 1/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Vascular disorders Shock	0.01% 1/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 1/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.00% 0/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.

Other adverse events

Other adverse events
Measure	qIRV: 18-64 Years n=9191 participants at risk Participants aged 18-64 years were randomized to receive a single dose of modRNA qIRV dose level 1 (low) IM on Day 1.	Licensed QIV: 18-64 Years n=9197 participants at risk Participants aged 18-64 years were randomized to receive a single dose of seasonal licensed QIV IM per IPM on Day 1.	qIRV: >=65 Years n=13557 participants at risk Participants aged \>=65 years were randomized to receive a single dose of qIRV dose level 2 (high) IM on Day 1.	Licensed QIV: >=65 Years n=13611 participants at risk Participants aged \>=65 years were randomized to receive a single dose of seasonal licensed QIV IM per IPM on Day 1.	qIRV (>=18 Years) n=22787 participants at risk Participants aged \>=18 years were randomized to receive a single dose of qIRV dose level 1 (low) and dose level 2 (high) IM on Day 1.	Licensed QIV: >=18 Years n=22808 participants at risk Participants aged \>=18 years were randomized to receive a single dose of seasonal licensed QIV IM per IPM on Day 1.
Gastrointestinal disorders Diarrhoea (DIARRHEA)	3.9% 355/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	3.6% 332/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	2.0% 272/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	1.7% 237/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	2.8% 627/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	2.5% 569/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
General disorders Chills (CHILLS)	8.0% 731/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	2.7% 249/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	4.3% 580/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.98% 133/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	5.8% 1311/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	1.7% 382/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
General disorders Fatigue (FATIGUE)	17.2% 1579/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	11.4% 1046/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	12.0% 1624/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	6.0% 812/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	14.1% 3203/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	8.1% 1858/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
General disorders Injection site erythema (REDNESS)	2.5% 230/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	1.1% 105/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	2.8% 376/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.70% 95/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	2.7% 606/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.88% 200/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
General disorders Injection site pain	1.5% 142/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.72% 66/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	2.0% 274/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.54% 74/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	1.8% 416/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.61% 140/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
General disorders Injection site pain (PAIN)	23.0% 2112/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	14.0% 1284/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	17.6% 2391/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	6.2% 840/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	19.8% 4503/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	9.3% 2124/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
General disorders Injection site swelling (SWELLING)	2.8% 254/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	1.4% 129/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	2.8% 383/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.95% 129/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	2.8% 637/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	1.1% 258/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
General disorders Pyrexia (FEVER)	1.8% 170/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.57% 52/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	1.5% 201/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.26% 36/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	1.6% 371/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	0.39% 88/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Musculoskeletal and connective tissue disorders Arthralgia (JOINT PAIN)	5.4% 493/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	2.3% 208/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	3.0% 407/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	1.5% 201/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	3.9% 900/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	1.8% 409/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Musculoskeletal and connective tissue disorders Myalgia (MUSCLE PAIN)	10.0% 920/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	3.3% 307/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	5.3% 715/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	1.8% 251/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	7.2% 1635/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	2.4% 558/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.
Nervous system disorders Headache (HEADACHE)	13.9% 1273/9191 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	9.3% 853/9197 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	7.7% 1043/13557 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	4.0% 543/13611 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	10.2% 2316/22787 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.	6.1% 1396/22808 • Local reactions/systemic events (Systematic assessment): from Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs: from vaccination 1 up to 6 months after last vaccination, other AEs: from vaccination 1 up to 4 weeks after last vaccination and All-cause mortality: From vaccination on Day 1 up to 6 months after vaccination. Same adverse event (preferred term) may appear as both non-SAE and SAE but are distinct events. An adverse event (preferred term) may be categorized as serious in 1 participant and non-serious in another. Safety population included all participants who received the study intervention at the specified dose level. Participants were included in the vaccination group corresponding to the study intervention that they actually received.

Additional Information

Pfizer ClinicalTrials.gov Call Center

Pfizer Inc.

Phone: 1-800-718-1021

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.
Publication restrictions are in place

Restriction type: OTHER